Synthesis of Phosphonate and Thiophosphonate Peptide Analogs as Inhibitors of Carboxypeptidase A. by Fan, Hong
Louisiana State University
LSU Digital Commons
LSU Historical Dissertations and Theses Graduate School
2000
Synthesis of Phosphonate and Thiophosphonate
Peptide Analogs as Inhibitors of Carboxypeptidase
A.
Hong Fan
Louisiana State University and Agricultural & Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses
This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in
LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact
gradetd@lsu.edu.
Recommended Citation
Fan, Hong, "Synthesis of Phosphonate and Thiophosphonate Peptide Analogs as Inhibitors of Carboxypeptidase A." (2000). LSU
Historical Dissertations and Theses. 7151.
https://digitalcommons.lsu.edu/gradschool_disstheses/7151
INFORMATION TO USERS
This manuscript has been reproduced from the microfilm master. UMI films the 
text directly from the original or copy submitted. Thus, some thesis and 
dissertation copies are in typewriter face, while others may be from any type of 
computer printer.
The quality of this reproduction is dependent upon the quality of the copy 
submitted. Broken or indistinct print, colored or poor quality illustrations and 
photographs, print bleedthrough, substandard margins, and improper alignment 
can adversely affect reproduction.
In the unlikely event that the author did not send UMI a complete manuscript and 
there are missing pages, these will be noted. Also, if unauthorized copyright 
material had to be removed, a note will indicate the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning 
the original, beginning at the upper left-hand comer and continuing from left to 
right in equal sections with small overlaps.
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6* x 9” black and white photographic 
prints are available for any photographs or illustrations appearing in this copy for 
an additional charge. Contact UMI directly to order.
Bell & Howell Information and Learning 
300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA
u t v l T
800-521-0600
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
R e p ro d u c e d  with perm iss ion  of th e  copyright ow ner.  F u r th e r  reproduction  prohibited without perm iss ion .
NOTE TO USERS
This reproduction is the best copy available
UMI
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
R e p ro d u c e d  with perm iss ion  of th e  copyright ow ner.  F u r th e r  reproduction  prohibited without perm iss ion .
SYNTHESIS OF PHOSPHONATE AND THIOPHOSPHONATE PEPTIDE 
ANALOGS AS INHIBITORS O F CARBOXYPEPTIDASE A
A Dissertation
Submitted to the Graduate Faculty of the 
Louisiana State University and 
Agricultural and Mechanical College 
in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy
in
The Department o f Chemistry
by 
Hong Fan
B.S., Beijing Institute of Chemical Technology, Beijing, China, 1990
May, 2000
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
UMI Number. 9963946
UMI*
UMI Microform9963946 
Copyright 2000 by Bell & Howell Information and Learning Company. 
All rights reserved. This microform edition is protected against 
unauthorized copying under Title 17, United States Code.
Bell & Howell Information and Learning Company 
300 North Zeeb Road 
P.O. Box 1346 
Ann Arbor. Ml 48106-1346
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ACKNOW LEDGEM ENTS
I would like to extend my deepest appreciation to my major professor, Dr. Robert P. 
Hammer, for his guidance, friendship, constant support throughout this work, his belief 
that students independently approach and solve problems, and conversely, his assistance 
when needed. I would to express my sincere gratitude to Dr. Robert M. Strongin for his 
encouragement and friendship. Special thanks are extended to Drs. Mark L. McLaughlin, 
Andrew Maverick, and Walter Keithly for being my committee members. They have 
always been helpful and concerned.
I would like to acknowledge the following people: Dr. Tracy McCarley, Dr. 
Wenzhe Lu, and Ms. Laura Baker for their patient assistance in mass spectral analysis; 
Dr. Dale Treleaven, Dr. Zhe Zhou for their assistance in NMR spectroscopy.
I cherish deeply the friendship o f all my lab mates, colleagues, and friends who 
made me feel part of a family during my stay in Baton Rouge.
I would like to express my appreciation to my wife, Judy Zhang, for her 
unconditional love and unwavering support, which have always been and continue to be 
the source of my strength and inspiration in my life. Also to my parents, Zheng Fan and 
Xiaoha Luo, for their understanding and spiritual assistance given, which have made this 
work possible.
ii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
TABLE O F CONTENTS
ACKNOW LEDGEM ENTS...................................................................................................... ii
LIST O F TABLES.......................................................................................................................v
LIST O F FIGURES....................................................................................................................vi
LIST O F SCHEM ES................................................................................................................. ix
LIST O F ABBREVIATIONS AND ACRONYM S........................................................... xii
ABSTRACT................................................................................................................................ xv
CHAPTER 1. IN TRO D U CTIO N .............................................................................................1
1.1 Enzymes and Their Inhibitors..............................................................................L
1.2 Carboxypeptidase A and Its Inhibitors..............................................................3
1.3 Synthesis of Phosphonate and Thiophosphonate Peptide Analogs...............8
1.4 Goal of the Project..............................................................................................15
CHAPTER 2. SYNTHESIS O F  AM INOPHOSPHONOUS ACIDS
AND T H E IR  D ERIV A TIV ES......................................................................18
2.1 Synthesis o f l-Amino-2-methylpropanephosphonous Acid........................18
2.2 Synthesis of 1-Amino-ethylphosphonous Acid............................................. 20
2.3 Protection o f Aminophosphonous Acid.......................................................... 20
2.3.1 Protection of N-terminal of Aminophosphonous Acid...................21
2.3.2 Protection of Phosphoninous Terminal............................................. 24
2.4 Experimental M aterial.......................................................................................26
CH APTER 3. SYNTHESIS O F PHOSPHONOPEPTIDE
ANALOGS BY USING ONE-POT PRO CED U RE................................36
3.1 Solid-Phase Synthesis........................................................................................36
3.2 SPPS with Amino Phosphonites...................................................................... 38
3.3 Solution Phase Synthesis of Phosphonopeptide Analogs..................46
3.3.1 S ynthesi s Phosphonite Dipeptide Analogs...................................... 46
3.3.2 Solution Phase One-pot Synthesis Approach..................................48
3.4 Summary..............................................................................................................6 6
3.5 Experiment M aterial..........................................................................................67
CH APTER 4. SYNTHESES O F PHOSPHONATE AND
TH IO PH O SPH O N A TE PEPTID E ANALOGS 
BY ESTERIFICATION-OXIDATION ST R A T E G Y .......................... 78
4.1 Synthesis o f Phosphonotripeptide Analogs................................................... 79
4.2 Ester Deprotection............................................................................................. 81
4.2.1 Deprotection of Methyl Esters............................................................81
4.2.2 Deallylation o f Allyl Esters................................................................83
iii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4.3 Enzyme Assays.................................................................................................. 90
4.4 Experimental Material...................................................................................... 92
REFERENCES.........................................................................................................................105
VITA......................................................................................................................................... 110
iv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LIST OF TABLES
Table 1.1 Inhibition o f CPA by tripeptide phosphonates................................................. 7
Table 3.1 Cleavage methods............................................................................................. 44
V
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LIST OF FIGURES
Figure 1.1 Hypothetical catalysis with changing the pathway of a reaction...................2
Figure 1.2.1 Mechanism for the peptide hydrolysis by carboxypetidase A6 ......................4
Figure 1.2.2 Examples o f early inhibitors of CPA ................................................................. 5
Figure 1.3 Thiophosphinyl inhibitors.................................................................................. 15
Figure 1.4 Target molecules..................................................................................................15
Figure 2.3 Non-participated protecting groups................................................................. 24
Figure 3.2.1 Solid support for peptide synthesis.................................................................. 41
Figure 3.2.2 2-Chlorotrityl resin..............................................................................................45
Figure 3.3.1 31P NMR spectra: A, activated species phosphonochloridite 37,
8  = 178.1; B, coupling product 3 8 , 8  = 136.7; C,
oxidation product 39 (before purification), 5 = 23.5-24.4;
triphenylphosphine oxide and its derivative, 8  = 27.3-35.8
in each spectrum ............................................................................................... 49
Figure 3.3.2 3IP NMR spectra: D, activated species phosphonochloridite 37,
8  = 177. 178.8; E, formation of cyclic phosphorus species 40,
8  = 194.6; F, oxophosphazole derivative 41, 8  = 34.1;
triphenylphosphine oxide and its derivative, 8  =  27.9-35.1
in each spectrum.................................................................................................51
Figure 3.3.3 31P NMR spectra: H , activated species 47, 8  = 182.0,184.1;
I, reaction with base to form 48 ,8  = 164.4, 166.1;
J , coupling product 49, 8  = 173.0, 173.6; K, sulfurization product,
5 1 ,8  = 76.5, 77.1,77.8, 78.1; 
triphenylphosphine oxide, 8  = 27.5, 27.7;
Ph3P = O H C l, 8  =  40.2..................................................................................... 57
Figure 3.3.4 Mechanism studies: (A) GC spectrum of 2-chloro-2-methyl-butane in 
DCM; (B) MS spectrum of 2-chloro-2-methyl-butane and library 
search result........................................................................................................ 60
Figure 3.3.5 Mechanism studies: (A) GC spectrum o f neopentyl chloride in DCM;
(B) MS spectrum of neopentyl chloride and library search result..............61
Figure 3.3.6 Mechanism studies: (A) GC spectrum o f reaction solution; (B) MS
spectrum o f the product and library search result.......................................62
vi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 4 Phosphonate and thiophosphonate peptide analogs.......................................78
Figure 4.1 l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride
(EDC)...................................................................................................................80
Figure 4.2.1 HPLC of Profile Z-Phe-A.la4'[(POS')O]-Phe-0Allyl 74. linear
gradient over 60 min of 65% solution A (0.25M ammonium 
acetate in H 2O) and 35% solution B (0.05M ammonium 
acetate in CH3 CN-H2O 4:1); purity 39%; tR= 15.9 min.............................. 84
Figure 4.2.2 HPLC of profiles of 50 and la .
(1) Z-Phe-Val4 /[(P0 2 ')0 ]-Phe-0 Allyl 50;linear gradient over 
60 min of 65% solution A (0.25M ammonium acetatein^O ) 
and 35% solution B (0.05M ammonium acetate in 
CH 3CN-H2O 4:l);purity 44%; tR = 15.1, 15.9 min.
(2) Z-Phe-Val4 / [(P0 2 ')0 ]-Phe-0 H la ;  linear gradient over 60 min 
of 65% solution A (0.25M ammonium acetate in H 2O) and 35% 
solution B (0.05M ammonium acetate in CH3 CN-H20  4:1);
purity 76%; tR =  10, 10.5 m in..........................................................................85
Figure 4.2.3 HPLC of profiles of 51 and lb .
(1) Z-Phe-ValvP[(P0S )0]-Phe-0A llyl 51; linear gradient over 
60 min of 65% solution A (0.25M ammonium acetate inH2 0 ) 
and 35% solution B (0.05M ammonium acetate in 
CH3CN-H2O 4:1); purity 42%; tR = 28.8min.
(2) Z-Phe-ValxF[(POS')OJ-Phe-OH lb;linear gradient over 60 min. 
of 65% solution A (0.25M ammonium acetate inH2 0 ) and 35% 
solution B (0.05M ammonium acetate in CH 3CN-H2O 4:1);
purity 8 8 %; tR= 9.7, 10.5 m in........................................................................8 6
Figure 4.2.4 HPLC of profiles of 76 and le .
(1) Z-Ala-Ala4/[(P0 2 ')0 ]-P he-0  Allyl
76; linear gradient over 60 min of 65% solution A (0.25M 
ammonium acetate inH2 0 ) and 35% solution B (0.05M ammonium 
acetate in CH3CN-H2O 4:1); purity 43%; tR= 17.2 min.
(2) Z-Ala-Ala'F[(P0 2 *)0 ]-Phe-0 H le; linear gradient over 60 min 
of 95% solution A (0.1M TEAA in H 2O) and 5% solution B (0.02M 
TEAA in CH 3CN-H2 O 4:1), flow rate 1 mL/min on a C-18 column; 
purity 6 %;tR= 24.6 min.................................................................................... 87
Figure 4.2.5 HPLC of profiles of 78 and If.
(1) Z-Ala-AIaxP[(P0S')0]-Phe-0A llyl 78; linear gradient over 
60 min of 65% solution A (0.25M ammonium acetate in H2O) and 
35% solution B (0.05M ammonium acetate in CH3 CN-H2O 4:1), 
purity 65%; tR= 15.8 min. (2) Z-Ala-AlalF[(POS)0]-Phe-OH If; 
linear gradient over 60 min o f 95% solution A (0.1M TEAA in H2 O)
vii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and 5% solution B (0.02M TEAA in CH3CN-H20  4:1), 
flow rate 1 mL/min on a C-18 column; purity 10%; 
tR = 24.1 min.......................................................................... 88
Figure 4.2.6 HPLC of profiles o f 72 and lc .
(1) Z-Phe-Ala¥[(PO:')0]-Phe-OAUyl 72; linear gradient over
60 min of 95% solution A (0.1M TEAA in H2 0 ) and 5% solution B 
(0.02M TEAA in CH 3CN-H20  4:1), flow rate 1 mL/min on a C-18 
column; purity 38%;tR= 23.5, 24.6 min.
(2) Z-Phe-AlalP[(PCK)0]-Phe-OH lc. linear gradient over 
60 min of 95% solution A (0.1M TEAA in H2 0 ) and 5% 
solution B (0.02M TEAA in CH3 CN-H20  4:1), flow rate
1 mL/min on a C-18 column; purity 62%;
tR= 28.7 min.....................................................................................................89
viii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LIST OF SCHEMES
Scheme 1.2 Haptens for catalytic antibody production...........................................6
Scheme 1.3.1 Retrosynthesis of phosphonopeptides.................................................. 9
Scheme 1.3.2 Phosphonyl chloride condensation route to phosphonopeptide 9
Scheme 1.3.3 Modified Mitsunobu route to phosphonopeptides............................. 10
Scheme 1.3.4 Solid-phase synthesis of phosphonopeptides from
Fmoc-protected phosphonodi peptides............................................... 10
Scheme 1.3.5 Solid-phase peptidylphosphonate synthesis cycle..............................12
Scheme 1.3.6 Synthesis of inhibitor library.................................................................13
Scheme 1.3.7 Synthesis of esters of phosphonodithioic acids.................................. 14
Scheme 1.4 Synthesis of phosphonate and thiophosphonate esters and
amides from H-phosphinates by a one-pot procedure.................... 17
Scheme 2.1.1 Preparation o f l-amino-2-methylpropanephosphonous acid (I)...19
Scheme 2.1.2 Preparation of l-amino-2-methylpropanephosphonous acid (II).. 19
Scheme 2.2 Synthesis of 1-amino-ethylphosphonous acid....................................20
Scheme 2.3 Formation of by-product during peptide synthesis............................21
Scheme 2.3.1.1 Fmoc protection o f aminophosphonous acids.....................................22
Scheme 2.3.1.2 Boc group protection of aminophosphonous acids.............................23
Scheme 2.3.1.3 Z group protection of aminophosphonous acids................................. 23
Scheme 2.3.1.4 Preparation of trityl-protected aminophosphonous acid.................. 24
Scheme 2.3.1.5 Preparation of (phthalimidomethyl)phosphonous acid.................... 25
Scheme 2.3.2 Esterification o f aminophosphonous acid
and alcohols with DCC/DMAP..........................................................25
Scheme 3.1 General approach to solid-phase peptide synthesis..........................37
ix
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Scheme 3.2.1 Solid-phase peptide synthesis phosphono and
thiophosphono peptide strategy.........................................................39
Scheme 3.2.2 Spectrophotometric assay54 for determining coupling yields
by analysis o f the Fmoc group. X =301 nm, £ = 7800 M*1cm '1....40
Scheme 3.2.3 Preparation of Fmoc-protected a-hydroxy acid.................................41
Scheme 3.2.4 Loading Fmoc-protected hydroxyl acid to resin................................42
Scheme 3.2.5 Formation of 5-keton-2-isopropyl-6-benzyl-1,4,2-
dizaphospholine, an analog of diketopiperazine (DKP)................ 43
Scheme 3.3.1.1 Synthesis o f phosphonite dipeptide analog........................................ 46
Scheme 3.3.1.2 Synthesis o f L-phenyllactic acid allyl ester....................................... 47
Scheme 3.3.2.1 One-pot synthesis procedure: addition of base
in the activation step...........................................................................48
Scheme 3.3.2.2 Formation of oxophosphazole derivative........................................... 50
Scheme 3.3.2.3 Preparation of resin-bound dichlorophosphorane............................. 52
Scheme 3.3.2.4 Synthesis o f Ph3 PF2 ..............................................................................53
Scheme 3.3.2.5 Formation of phosphonyltrialkylammonium salts............................53
Scheme 3.3.2.6 One-pot synthesis procedure: addition of base
after activation step............................................................................. 54
Scheme 3.3.2.7 Few er equivalents o f Ph3PCl2 caused no coupling of
hydroxy acid ester............................................................................... 56
Scheme 3.3.2.8 Proposed mechanism of phosphonodichloridite formation............ 59
Scheme 3.3.2.9 DIEA resins as potential nucleophile in activation of
Phosphonites........................................................................................ 64
Scheme 3.4 Side Reactions in phosphonous ester activation with Ph3PCl2  65
Scheme 4.1.1 Synthesis o f H-phosphonites tripeptide analogs.............................. 79
Scheme 4.1.2 Oxidation o f H-phosphinates............................................................. 80
x
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Scheme 4.1.3 Sulfurization of H-phosphinates......................................................... 81
Scheme 4.2.1 Deprotection of methyl esters............................................................. 82
Scheme 4.2.2.1 The mechanism of allyl group deprotection..................................... 83
Scheme 4.2.2.2 Preparation o f tetrakis(triphenylphosphine) palladium (0)..............83
Scheme 4.2.2.3 Deallylation o f allyl esters...................................................................84
Scheme 4.2.2.4 Possible mechanism of Desulfurization of
thiophosphonopeptide to phosphonopeptide................................. 90
Scheme 4.3 Kinetic enzyme assay to measure dissociate of inhibitors from
carboxypeptidase (CPA): rate of NADH production is 
measured by fluorescence (Xex = 340 nm; Aem = 450 nm) 
and is proportional to [CPAfree] ........................................................ 91
xi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
LIST OF ABBREVIATIONS AND ACRONYMS
AAi amino acid
Ala (A) alanine
Arg arginine
Asn asparagine
Boc /err-butyloxycarbonyl
Boc-ON 2-(rm-butyloxycarbonyoxyimino)-2-phenyIacetonitrile
BOP benzotriazol-l-yloxy-tris(dimethylamino)phosphonium
hexafluorophosphate
r-BuOH /erf-butanol
Calc’d calculated
CH3CN acetonitrile
CPA carboxypeptidase A
DBU 1,8-diazabicyclo[5,4,0]undec-7-ene
DCC /V.W’-dicyclohexycarbodiimide
DIAD diisopropyiazodicarboxylate
DIEA W.Af-diisopropylethylamine
DMAP 4-dimethylaminopyridine
DMF N, N-dimethyl formamide
DMSO dimethylsulfoxide
EDC l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride
EtOAc ethyl acetate
EtOH ethanol
FAB-MS fast atom bombardment mass spectrometry
xit
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
fM femptomolar
Fmoc 9-fluorenylmethyloxyarbonyl
Fmoc-Cl 9-fluorenylmethyl chloroformate
GC gas chromatography
Glu glutamine
HATU 0-(7-azabenzotriazol-l -yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate
HBTU 2-( l//-benzotriazol-1 -yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate
HOBt 1 -hydroxybenzotriazole
HPLC high pressure liquid chromatography
HRMS high resolution mass spectrometry
Hz hertz
MeOH methanol
nM nanomolar
NMR nuclear magnetic resonance
PAC 4-hydroxymethylphenoxyacetic acid
PEG-PS polyethylene glycol-polystyrene resin
Phe (F) phenylalanine
pM picomolar
Prot protected
SPPS solid-phase peptide synthesis
TBAF tetrabutylammonium fluoride
TEA triethylamine
xiii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
TEAA triethylammonium acetate
TEAB triethylammonium bicarbonate
TFA trifluoroacetic acid
THF tetrahydrofuran
trityl triphenylmethyl
Tyr tyrosine
(iM micro molar
Val (V) valine
Z AHbenzyloxycarbonyl)
Z-OSu Ar-(benzyloxycarbonyloxy)succinimide
xiv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ABSTRACT
Phosphonate analogs of peptides are important in biochemical research and potentially as 
medicinal agents because of their ability to strongly inhibit both metallo and aspartyl 
proteases. Although a number of phosphorus-containing molecules were reported as 
inhibitors for carboxypeptidase A (CPA, there have been only a few 
thiophosphonopeptide inhibitors reported. There has been no investigation in which the 
K\ values of a series of thiophosphonate inhibitors was compared to the analogous 
phosphonates to probe the role the sulfur atom in inhibition. The goal of this work is to 
prepare phosphonopeptide inhibitors of CPA and their thio-analogs so that this 
comparison can be made. To accomplish this goal, we have utilized reduced phosphorus 
[P(IH)J intermediates in an activation-coupling-oxidation protocol both on solid support 
and in solution. In the solid-phase synthesis, only moderate yields of the protected amino 
phosphonite coupling were achieved (40-70%). Also, no full-length products were 
obtained due to a stable 6 -membered cyclic oxazaphospholine formed during the 
deblocking step of the resin-bound phosphonodipeptide. In solution-phase synthesis, 
activation in the presence of base provides phosphonochloridite, which produces 
oxaphosphazoles that are unreactive towards alcohols, which explains low yields. 
Activation in the absence of base produces phosphonodichlorite, which does provide 
phosphonopeptides, but lacking the ester protection.
An alternate route to CPA inhibitors that utilizes H-phosphonate esters as key 
intermediates successful produced a phosphonopeptide CPA inhibitor and its thio-analog. 
Preliminary enzyme assays found that phosphonopeptide peptide analog has a K, value of 
1 0 14 M, and thio-analog has a K\ value of about 10' 15 M. This indicates that
XV
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thiophosphonate peptide analog is among the lowest values yet determined for protease 
inhibition.
Several of desired targets could not be prepared because of difficulties with C- 
terminal ester cleavage. Cleavage of methyl ester with thiolate led to decomposition for 
peptides with a phosphonoalanine analog. Allyl ester cleavage with palladium was 
successful for phosphonates, but not in general for thiophosphonates. The 
thiophosphonate sulfur' may react with the palladium catalyst to form a thioallyl ester, 
which during the aqueous workup process is hydrolyzed to displace the sulfur moiety.
xvi
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CHAPTER 1. INTRODUCTION
1.1 Enzymes and Their Inhibitors
Enzymes are remarkably effective catalysts, responsible for the thousands of coordinated 
chemical reactions involved in biological processes of living systems. Most enzyme 
reactions take place very rapidly, as compared with perhaps a year for some reactions in 
the absence of enzymes. Indeed, most reactions in biological systems do not occur at 
perceptible rates in the absence o f enzymes. For example, carbonic anhydrase is an 
enzyme that catalyzes the hydration of carbon dioxide. Each molecule o f this enzyme 
can hydrate 105 molecules of carbon dioxide per second. This catalyzed reaction is 107 
times faster than the uncatalyzed one . 1
An enzyme accelerates the rate o f a reaction by lowering the free energy of 
transition-state required for conversion of reactants to products. The pathways of the 
enzyme and non-enzyme reactions can in principle be described by a variety of paths that 
resemble each other in energy." More accurately, the enzyme changes the pathway of the 
reaction to a pathway having a lower free energy of activation, and provides an 
alternative and more speedy reaction route (Fig. 1.1) . 3
The inhibition of enzymatic activity by specific small molecules and ions is 
important because it serves as a major control mechanism in biological systems. 
Inhibitors are of great us pharmaceuticals and pesticides, since “an unnatural substrate 
analog can block the action of a specific enzyme” .4  Such inhibitors are commonly used to 
probe the chemical and conformational nature of a substrate-binding site as part of an 
effort to elucidate the enzyme’s catalytic mechanism and role in a metabolic process.
I
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Many inhibitors are substances that structurally resemble their enzyme’s substrates but 
either do not react or react very slowly compared to substrates. These inhibitors can 
compete directly with a normal substrate for an enzymatic-binding site and are known as 
competitive inhibitors. One approach to designing competitive inhibitors is as a mimic of 
a transition state of a reaction catalyzed by the enzyme. The criteria for defining a 
competitor inhibitor as a transition state analog of an enzyme are first, the inhibitor must 
bind more tightly to the enzyme than does the substrate; second, the conformation of the 
inhibitor is consistent with the structure of the transition state postulated for the enzyme- 
catalyzed reaction . 5  The approach to design of transition state analog inhibitors is 
therefore to find stable molecules which resemble the reaction intermediates.
Uncatalyzed
reaction
Catalyzed 
\  reaction
AG
Reactant
product
Reaction coordinate
Fig. 1.1 Hypothetical catalysis with changing the pathway of a reaction.
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1.2 Carboxypeptidase A and Its Inhibitors
Carboxypeptidase A (CPA) is a Zn2+-containing digestive enzyme that catalyzes the 
hydrolysis of the carboxyl-terminal peptide bond in polypeptide chains. Hydrolysis 
occurs most readily if  the carboxyl-terminal residue has an aromatic or a bulky aliphatic 
side chain . 5 CPA is a protein with molecular weight of 34,472 containing one zinc ion 
bound to a single polypeptide chain of 307 amino acids. Important residues for catalysis 
and binding are Glu 270, Arg 71, Arg 127, Asn 144, Arg 145, Tyr 248, and Zn2+. Tyr 
248 is confirmed as a residue that is important for substrate binding, probably by 
hydrogen bonding via its phenolic hydroxyl moiety. The enzyme contains a zinc atom 
and other groups at its active site that induce rearrangements in the electronic distribution 
of the substrate, thereby rendering it more susceptible to hydrolysis (Fig. 1.2.1 a) . 6
Proteins and peptides are stable at neutral pH in the absence of a protease because 
water does not readily attack peptide bonds. A key catalytic task of carboxypeptidase A 
is to activate water. The mechanism for peptide hydrolysis by carboxypeptidase A 
involves the three steps (Figure 1.2.1) : 6 (a) the precatalytic Michaelis complex with the 
substrate carbonyl hydrogen bonded to Arg-127 allows for nucleophilic attack by a water 
molecule promoted by zinc and assisted by Glu-270; (b) the tetrahedral intermediate 
stabilized by both Zn2+ and Arg-127. In this complex, the zinc ion is five-coordinated, 
and the Glu-270 is in a position to be hydrogen bonded to the tetrahedral intermediate; (c) 
the final step is the transfer of a proton from the COOH group of Glu-270 to the peptide 
NH group. The peptide bond is concomitantly cleaved, and the reaction products diffuse 
away from the active site.
3
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Fig. 1.2.1 Mechanism for the peptide hydrolysis by carboxypetidase A . 6
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Fig. 1.2.2 Examples of early inhibitors of CPA.
Quite a few inhibitors for CPA have been reported. In the early days, 7  protein 
chemists found an inhibitor, 3-phenylpropionic acid I, designed after a simple substrate 
with the value o f an inhibition constant, Ku of 10' 3 M. Byers and Wolfenden8 designed a 
CPA inhibitor L-2-benzylsuccinic acid II which was a 1000-fold more potent than 
inhibitor I (Ki = 6  x 10‘7  M). Then, Hofmann and Rottenberg5 prepared a transition state 
analog, L-2-phosphoryloxy-3-phenylpropionic acid III, in which the carbon of the 
presumed tetrahedral intermediate (Fig. 1.2.1 b) was replaced by a phosphorus atom. The 
inhibition constant K\ was improved to 1.4 x 10‘7M (Fig. 1.2.2).
Phosphonopeptides are peptide analogs in which an amide linkage has been 
replaced with a phosphonate ester or phosphonamide. Phosphonate analogs of peptides 
are important in biochemical research and potentially as medicinal agents because o f their 
ability to strongly inhibit both metallo9 ,1 0  and aspartyl proteases. 11 ,12 In addition, 
phosphonate esters have been used as haptens for the production o f catalytic antibodies 
possessing esterase activity (Scheme 1.2) . 13 The basis for this inhibitor action is 
attributed to the similarity o f the tetrahedral phosphorus species to a presumed tetrahedral 
intermediate arising from addition o f a zinc-bound water molecule to the substrate
5
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carbonyl group. 1 4  The insertion of a phosphonate unit in the place of the scissile amide 
bond of a substrate provides access to the additional binding interactions available within 
the enzyme substrate complex as it approaches its transition-state conformation . 13
Catalytic
Antibody
0 2N
H ? Vnh 
v ^ K nH2
O R H H o
H 0 .  0  ( ' ' V n H 
O 0  ^  0
o NH
Proposed intermediate Hapten used  to generate catalytic antibody
Scheme 1.2 Haptens for catalytic antibody production.
In the last decades, more research has been focused on transition state analog 
inhibitors. In 1981, Bartlett et al. 16 synthesized a phosphonamidate dipeptide analog N- 
[[[(benzyloxycarbonyl)amino]methyl]hydroxyphosphinyl]-L-phenylalanine, dilithium 
salt as an inhibitor of CPA with K \ -  6  x 10‘9  M. The molecule was a mimic of the 
substrate Z-GIy-L-Phe-OH with a tetrahedral phosphonamide moiety in the place of the
6
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scissile peptide group. This indicated a new strategy for the design o f transition state 
analogs of many enzymes. Also, phosphonate analogs have been prepared as inhibitors 
of other Zn-proteases like thermolysin , 17 esterases such as leukocyte elastase , 18 as well as 
haptens for the production of catalytic antibodies. 19
Since then, a number of phosphorus-containing inhibitors have been reported for 
CPA with inhibition constants from jliM  to fM range . 2 0 ,2 1  Phosphorus-containing 
tripeptides, such as Z-Phe-Val\j/[P(02 ')]Phe-OH, were found to have K\ for inhibition of 
CPA in the range of 10-27 fM. The investigation led to the determination o f what they 
believed to be the lowest inhibition constant and slowest dissociation rate constant 
measured for a low molecular weight enzyme inhibitor. 2 2
Table 1.1: Inhibition of CPA by tripeptide phosphonates.
entry inhibitor ^ ( K P M V ) *off(10‘V ) tfi(pM )
1 Boc-AIa-Alay[P(02 )0]Ala-OH 
Abbrev.: [BocAAp(0)A]
646 000
2 Z-Ala-Ala\|/[P(02 )0]A la-0H  
Abbrev.: [ZAAp(0)A]
76 000
3 Z-Phe-Ala\|/[P(02 ')0]A la-0H  
Abbrev.: [ZFAp(0)A]
56 000
4 Boc-T yr-Alai|/[P(02‘)0] Ala-OH 
Abbrev.: [BocYAp(0)A]
24 500
(table continued)
7
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5 Z-T yr-Ala\|f [P (0 2 ‘)O] Ala-OH 
Abbrev.: [ZYAp(0)A ]
5 6000  0 0 0 1 2  0 0 0
6 Z-Ala-Glyi|/[P(02 *)0]Phe-0H 
Abbrev.: [ZAGp(0)F]
6 . 6 470 000 710
7 Boc-Tyr-Valy[P(02 ')0]A la-O H  
Abbrev.: [BocYVp(0)A ]
0.276 1 1 0 0 0 370
8 Z-Ala-Phe\|/[P(02 ')0 ]P h e-0 H  
Abbrev.: [ZAFp(0)F]
2 . 0 800 4
9 Z-Ala-Alai|A[P(02 ')0 ]P he-0H  
Abbrev.: [ZAAp(0)F]
2 . 1 750 3
1 0 Z-Phe-Ala\|f[P(02 )0 ]P he-0H  
Abbrev.: [ZFAp(0)F]
2 . 2 2 2 0 I
1 1 Z-Phe-V alv[P(0 2 -)0]Phe-0H  
Abbrev.: [ZFVp(0)F]
2 . 1 2.9 0.014
1.3 Synthesis of Phosphonate and Thiophosphonate Peptide Analogs
Phosphonates and phosphonamides are generally prepared by the reaction of 
phosphonochloridates or phosphonodichloridates with alcohols or amines. The 
chloridates are obtained from phosphonate diesters with phosphorus pentachloride , 2 3 -2 4  or 
by selective base hydrolysis of phosphonate diesters to the monoesters followed by 
reaction with thionyl chloride2 5 ,2 6 ,2 7  o r oxalyl choride (scheme I.3.2 . ) . 2 8 '2 9 ,3 0 '31 In 
addition, the synthesis o f phosphonopeptides by using BOP-phosphonate ester3 2  and 
modified Mitsunobu strategies15 have been reported (Scheme 1.3.3).
8
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Phosphonochloridate 
P(V)
U Un R
P hosphonate/ Mitsunobu 
P(V)
Prot
w 0•IUkN
m H _v\ iqY f T 1m
in s
j j ' S r
v QiV /*
X'H X = 0 ,  NH 
Y = 0 ,  S 
Z = 0 , S
n
Prot>
P(lll)
0• •
P(lll)
R
Phosphonoch loridite
Rn+1
H-Phosphinate 
R = H, or OR = active e s te r
Scheme 1.3.1 Retrosynthesis of phosphonopeptides.
peptide
HXSOOI2 I rt II _ Rg
r , _ 9 _ o h  O t o o c f t i .  J L  0  ■ o  J L , A ^ p e p . w „
0R2 o r 2 or2 0
X = 0 ,  N
Ri. r2. r3= AIM groups
Scheme 1.3.2 Phosphonyl chloride condensation route to phosphonopeptides.
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HO
r3
peptide
T
R ,-F>-O H
Peptide
OR2 Ph3P/DIAD OR2 0
R1. R2. r 3= Alkyl groups
Scheme 1.3.3 Mitsunobu condensation route to phosphonopeptides.
H
F m oc-N
H3CO
1. SOCI2/  c h 2ci2
2. HCI. Gly-OAIlyl 
Et3N/CH2CI2 H
------------------------  Fm oc-I
H3CO
H2/Pd-C 
EfOH/ H20
HA 'P ^
F m o c-N  PN _©
HaCO Y Y
HA PAc-AlaN P '/ \
h3co  nn^ t ° -V a l-V a l-A h x -O H
Scheme 1.3.4 Solid-phase synthesis of phosphonopeptides from Fmoc- 
phosphonodipeptides.
In order to improve phosphonopeptide synthesis, several groups have 
incorporated phosphonate amino acids into peptide chains by solid-phase methods. This 
allows for use of excess reagents to help compensate for the slow kinetics and reduces the 
need for purification. The advantages of a solid-phase synthesis, including high yields 
and ease o f workup, would facilitate the synthesis of these important compounds. In 
addition, the methodology would enable the construction of combinatorial
1 0
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peptidylposphonate libraries. In Maffre-Lafon’s strategy , 2 3  the solid-phase synthesis of 
two phosphonopeptides was carried out from an iV-Fmoc protected dipeptide precursor 
with the P-N bond established. The target molecules were synthesized by coupling the 
dipeptides to the N-terminal peptidyl resin using BOP/DIEA as reagents. While this 
method was effective for incorporation of a phosphonamide linkage into a peptide, it 
required that protected phosphonamide dipeptides first be prepared in solution (Scheme 
1.3.4). Campbell and Bermak described solid-phase synthesis o f peptidylphosphonates 
using a modified Mitsunobu coupling procedure , 3 3  in which the alcohol was condensed 
with a methyl [N-(4-nitrophenethyloxycarbonyl)amino] alklyphosphonic acid, providing 
the peptidylphosphonate with inversion of configuration at the carbinol carbon. The 
betaine formed between the phosphine and dialkyl azodicarboxylate (DIAD) was basic 
enough to cause removal of the Fmoc group, necessitating the use o f the more stable 
protecting group 4-nitrophenethyloxycarbonyI (NPEOC). The deprotection of the 
NPEOC group was accomplished with 5% DBU. Coupling yields o f greater than 90% 
were obtained (Scheme 1.3.5). However, these reactions were highly dependent on steric 
factors and couplings could take more than 1 2  hours to go to completion.
Subsequently, Campbell and coworkers reported the application of their method 
to the construction and screening of a phosphonopeptide library and characterization of 
its interactions with thermolysin, a well-studied zinc endopeptidase from Bacillus 
thermoproteolyticus (Scheme 1.3.6 ) . 3 4
The library o f peptidylphosphonate sequences (Z-AP-°B-C-resin) was constructed 
on non-cleavable resin. The C residue (P2 ’ position) consisted o f 18 amino acids. Five 
hydroxyl acids were used at the °B residue (P i’ position) and six aminoalkylphosphonic
tl
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acids at the Ap residue (Pi position). This resulted in the generation of 540
peptidylphosphonates within the library. The library was assayed for thermolysin 
inhibition. After each round of screening, the most active pool was selected for 
deconvolution. Each subpool was then synthesized and assayed with the most active 
mixtures then chosen for the next round of screening.
1) pyperidine
2) HBTU, HOBt, DIEA + 0
Fmoc-NH-(peptide) ~ m --------------- 3 —  Fm“ " °
F m o c-O ^ A QH R, H
Ri
1) piperidine
2) tris(4-chlorophenyl)phosphine, R2 0
OIAD, DIEA H .A . O .A .
NPEOC— N Pv v T 'N - ( p e p t i d e )
5 * 0  H3“ '  O fi, H
N P E O C -N  P - q h  
h  ' r . 1) 5% DBU
2) Fmoc-amino acid, 
HOBt, HBTU
R2  O
h A  . o ^  J L
H2N—(peptide)— N P, ^ r ^ N —(peptide)
H3CO x0  H
TFA, scavengers
R2  O
H2N—(peptide)— N ^ P ( ' ° ' V ^ S'N —(peptide) 
HO O  R: , H
Scheme 1.3.5 Solid-phase peptidylphosphonate synthesis cycle.
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0
Fmoc-AA-OH u  ..  II
h 2 n - W   -------------- ► h 2 n y ^ h
P— i N
2
u  0H ii
N P E O O -N v ,F=-OH 
T  OMe
Pi
F m oc-O .
Pi‘
? 1‘ H 0
ho> Y NV ^ n 
0  H
MeOv 0  f i ’ H 9
HzNY  oA Y 'n v A n- 
P, O H
H0> «P V  H 9 z - h n ^ ^ n  ^ X H
P , O P  2 H
Library Parent Structure (Z-Ap-°B-C-resin)
Scheme 1.3.6 Synthesis of inhibitor library.
Both phosphonic and thiophosphonic compounds can be considered as transition 
state analog inhibitors due to the presence of a tetrahedrally hybridized phosphorus atom 
at the position occupied by a trigonal planar carbon atom in the ground state of the 
substrate. Nishino found N“-thiophospho-L-phenylalanyl-L-aIanylglycine amide IV (Kt
7.0 jiM) to be somewhat less potent than A^-phospho-L-phenylalanyl-L-alanylglycine 
amide (Kt 2.6 (iM) in inhibiting the zinc metalloproteinase thermolysin . 33 Grobelny et al.
13
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reported that the sulfur analog, 2-benzyl-3-(0-ethylthiophosphono)propionic acid V (Fig. 
1.3), had a K\ of 2.1 pM, nearly as active as (2/?5)-2-benzyl-3-(0- 
ethylphosphono)propionic acid . 2 0  Although many methods exist to prepare simple 
phosphonic acids and their derivatives, there are few techniques available for the 
synthesis of highly functionalized phosphonates in which a sulfur is a substitute for one 
or more of the oxygen atoms. In Sampson’s paper, PhSH was used to prepare 
thiophosphinyl compound VI as a suicide inhibitor of serine protease (Fig. 1.3) . 18 Martin 
et al. reported a general procedure for the synthesis of esters o f phosphonodithioic 
acids . 36 The method involved the reaction of the Grignard reagents with 2-chloro-1,3,2- 
dithiaphospholane to give intermediate dithiophosphinates that were sulfurized using 
elemental sulfur to provide the intermediate phosphonotrithioates. This reaction with a 
variety of alcohols in the presence of DBU furnished the desired phosphonodithioates 
(Scheme 1.3.7).
, S ^  R-MgX /S '» I Sa
Cl"  v ------------------- "  R" P' ^
© ©
s  s  HOCH2CH2NMe3 OTs S @
> '  "1  ► r - p - o c h 2c h 2ni
S DBU ^
Scheme 1.3.7 Synthesis of esters of phosphonodithioic acids.
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H 1 11
V| n  S P h  0
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u  i II 0
M H 0
Fig. 1.3 Thiophosphinyl inhibitors.
1.4. Goal o f the Project
2  R1 H X" \  In  
1
1a: R ^ B n , R2=/Pr, X =0; 1b: R 1=Bn, R2=/Pr, X=S; 
1c: R 1=Bn, R2=Me, X=0; 1d: R1=Bn, R2=Me, X=S; 
1e: R 1=Me, R2=Me, X=0; 1f: R ’=Me, R2=Me, X=S;
Fig. 1.4 Target molecules.
In the 1980s, a number o f phosphorus-containing molecules were reported as inhibitors 
for carboxypeptidase A. However, there have been only a few thiophosphonopeptide 
inhibitors reported. There has been no investigation in which the AT* values of a series of 
thiophosphonate inhibitors was compared to the analogous phosphonates to probe the
15
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role the sulfur atom in inhibition. We therefore set out to prepare target 
phosphonopeptides la , lc , le  and thiophosphonopeptides lb , Id, If to make this 
comparison (Fig. 1.4).
To accomplish this goal, we planned to employ a new method. Our laboratory 
had previously developed preparing phosphonate, phosphonamide, thiophsphonate and 
thiophosphonamide peptide analogs . 3 7  In this approach (Scheme 1.4), 
Y-acyl/alkoxylcarbonyl a-amino-phosphonous acid (H-phosphinate) esters were 
activated with dichlorotriphenylphosphorane (Ph. PCI,) to produce a highly reactive 
trivalent species (phosphonochloridites, Scheme 1.4), which was used in the coupling 
step with an alcohol or an amine (IDOL) to provide phosphonites. In nucleoside 
chemistry, it is known that nucleophilic displacement is much faster at P(III) than at P(V) 
centers. 3 8  The resulting phosphonous [P(m )] tripeptide analogs were then oxidized or 
sulfurized to the desired phosphonates (X =0, Y =0), thiophosphonates (X =0, Y=S), 
phosphonamides (X=NH, Y =0), and thiophosphonamides (X=NH, Y=S). Another goal 
of this project is to develop general methodologies for the preparation of phosphonate 
and thiophosphonate derivatives as CPA inhibitors, in which reduced phosphorus [P(III)] 
intermediates are used as a way to potentially improve both the yield and accessibility of 
these valuable peptide mimics. This would allow these important molecules to be more 
readily available for biological and medicinal applications and, additionally, new 
derivatives with sulfur ligands on phosphorus could be easily prepared. The remaine of 
this dissertation is broken into three main parts: (1) Synthesis of phosphonate amino acids 
suitable for use in the preparation of CPA inhibitors 1 by the method in Scheme 1.4; (2) 
Investigations into solid-phase and solution phase protocols for preparation o f 1 by the 
activation-coupling-oxidation protocol and mechanistic studies into several aspects of
16
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this protocol, which explain low yields and side reactions; and (3) Development of an 
alternate route to CPA inhibitors 1 that utilizes H-phosphonate esters as key 
intermediates, which resulted in the first direct comparison of the K* of a known 
phosphonopeptide CPA inhibitor with its thiophosphonate analog.
Ri
P ro t-N  P -O R 2 —  
H H
am inophosphinate P(lll)
P h3PCI2
j \ y
P ep tid e-N  P^-XR3 
OR2
additional coupling
H
P ro t-N
OR. HXR.
P ro t-N
[0] or [S]
X=N, O; Y=0, S
Scheme 1.4 Synthesis of phosphonate and thiophosphonate esters and amides from 
H-phosphinates by a one-pot procedure.
17
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2. SYNTHESIS OF AMINOALKYLPHOSPHONOUS 
ACIDS AND THEIR DERIVATIVES
According to the retrosynthetic analysis in scheme 1.3.1, aminoalkylphosphonous acids 
and their derivatives were chosen as starting reagents to prepare the phosphonate and 
thiophosphonate peptide analogs. A general method to prepare functionalized 
aminoalkyphosphonous acids was published by Baylis et al. / 9  and consisted of the 
addition of hypophosphorous acid (or derivatives) to /V-(diphenylmethyl)imines. Jiao et 
al. 4 0  reported an one-pot method to synthesize differently functionalized 
aminoalkyphosphonous acids, using an addition of bis(trimethylsilyl) phosphonite to N- 
tritylalkanimines. Both of these methods were employed in this work to prepare 
aminoalkylphosphonous acids. 9-Fluorenylmethoxycarbonyl (Fmoc), tert- 
butoxycarbonyl group (Boc), benzyloxycarbonyl (Z) and triphenylmethyl (trityl) groups 
were used to protect the N-terminus and various esters were prepared to block 
phosphonite terminals.
2.1 Synthesis of l-Amino-2-methylpropanephosphonous Acid
l-Amino-2-methylpropanephosphonous acid 6  was the starting point for the synthesis of 
the target molecules carboxypeptidase inhibitors Z-F-V-*P[(P0 2 > ( 0 )1F-0 H and Z-F-V- 
'F [(P0S>(0)]F-0H . According to Haemers et al. , 4 0  a solution of the protected imine 2 
in chloroform was added to the in-situ-generated bis(trimethylsilyl) phosphonite 441 to 
generate fully protected amino acid 6 . Cleavage of the silyl and benzyl groups by 
hydrogen chloride provide, after removal of the solvent, aminophosphonous acid 6 , 
which was isolated from an EtOH solution by addition of propylene oxide to scavenge 
hydrogen chloride (yield 56%) (Scheme 2.1.1).
18
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Ph3CCI
NCPh;
R. T./ 2 days ethanol/reflux/12 h
n h 4o h  O
11
   HPH
reflux/8 h
1) MeOH/HCI
2) ethanol/ 
propylene oxide
Scheme 2.1.1 Preparation o f l-amino-2-methyIpropanephosphonous acid (I).
0
© © ph
Ph2CHNH3 H3P 0 2 ---------------------------  M [J 0 H
Ph
8
HBr/refluxing
h 2n  p - o h  
H
Scheme 2.1.2 Preparation of l-amino-2-methyIpropanephosphonous acid (II).
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Alternatively, reaction o f the diphenylmethylamine salt o f hypophosphorous acid 
7 with aldehyde in refluxing EtOH, followed by treatment with 49% HBr to cleave 
diphenylmethyl group gave the same product in 47% yield (Scheme 2.1.2) . 39
The yields of these two strategies were about the same. But since the latter one 
takes less time, it was applied for synthesis of compound 6 .
2.2 Synthesis of 1-Amino-ethylphosphonous Acid
Acetaldehyde in water was added dropwise to a refluxing solution of 
diphenylmethylamine hydrochloride and 50% aqueous hypophosphorous acid to form 
diphenylmethlyamino-ethylphosphonous acid. The product was treated with 18% HC1 
and the solvent was evaporated. The residue was dissolved in EtOH and propylene oxide 
was added dropwise to precipitate the aminophosphonous acid 9 (Scheme 2.2 ) / 9
o  IH 2 PO3 /H2 O _
®  ^  2.Acetaldehyde/H20  JL /,
P h2CHNH3 Cl -------------------------------- ► PhjHC-HN P -O H
H
1. HCI (18% ) I
2.propylene oxide //
H2N P -O H  
H
9
Scheme 2.2 Synthesis o f 1 -amino-ethylphosphonous acid.
2.3 Protection of Aminophosphonous Acids
When a chemical reaction is to be carried out selectively at one reactive site in a 
multifunctional compound, other sites must be temporarily blocked. A protecting group 
must fulfill a number o f requirements. It must react selectively in good yield to give a
20
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protected substrate that is stable to the projected reaction. The protecting group must be 
selectively removed in good yield. The protecting group should form a derivative that 
can easily be separated from side products associated with its formation or cleavage . 4 2
In the preparation of even the smallest peptide, it becomes obvious that certain 
functional groups must be blocked 4 3  For example, to prepare dipeptide AAj-AAi, amino 
acid AAj has to be coupled with amino acid AAi. In order to acylate the amino group of 
the amino-component AA2 , we have to activate the carboxyl group of the AA[. The 
activated carboxyl-component can acylate, however, not only the amino-component of 
A A i, but also the amino group of AAi to yield AAj-AAj, instead of the desired AA 1-AA2 . 
To prevent such unwanted by-products during peptide synthesis, Fmoc, Boc, trityl and Z 
groups are used to block the amino side, while a variety of esters are utilized to protect 
the carboxyl terminal.
i1 i 1 H jL
h 2n " \ - x  + h 2n a v - x  — ► H2N ^ y N v f  x
0  o  0  Rt
AA1 AAj AAj—AAj
Scheme 2.3 Formation of by-product during peptide synthesis.
2.3.1. Protection of ^ terminal of Aminophosphonous Acids
The 9-fluorenylmethoxycarbonyl (Fmoc) group is a contribution from the Carpino 
laboratory to solution-phase peptide synthesis and has most successfully adapted to solid- 
phase peptide synthesis of peptides. 4 4  The Fmoc group is exceptionally stable towards 
acid, and can easily be removed in the presence of mild base. The /V-protected Fmoc- 
aminophosphonous acid 10 was obtained with 93% yields by addition of 9-
2 1
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fluorenylmethyl chloroformate (Fmoc-Cl) to a solution of the 6  in water/dioxane mixture 
at controlled pH (9-9.5) (Scheme 2.3.1) . 43
Dioxane/water
Fmoc-C! +  H2N
Fmoc
Scheme 2.3.1.1 Fmoc protection of aminophosphonous acids.
The ferr-butoxycarbonyl group (Boc) remains one of the most frequently used
amino protecting groups. Being inert towards catalytic hydrogenolysis and extremely
resistant towards basic and nucleophilic reagents makes it an ideal orthogonal partner to
benzyl esters and carbamates used in peptide synthesis.4 6  l-Amino-2-
methylpropylphosphonous acid 6  was treated 2 -(rm-butyloxycarbonyoxyimino)-2 -
phenylacetonitrile (Boc-ON) and triethylamine in DMF to form l-[JV-(r-
18butoxycarbonyl)amino]-2-methylpropylphosphonous acid 11 (Scheme 2.3.1.2.).
The benzyloxycarbonyl group (Z) fits well into a variety of orthogonal protecting 
group strategies since it can be cleaved by dissolving metal reduction, catalytic 
hydrogenation, and strong acids (e.g. HBr in acetic acid). Z-protected
aminophosphonous acid 1 2  was prepared by dissolving N- 
(benzyloxycarbonyloxy)succinimide (Z-OSu) in dimethoxyethane and slowly adding I-
22
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amino-2 -methylpropylphosphonous acid dissolved in 1 0 % NajCC^ at room 
temperature. 4 7  The mixture was stirred overnight. After working up, Z-protected 
aminophosphonous acid 12 was obtained in 81% yield (Scheme 2.3.1.3).
P  DMF A .  P
H2N P - O H  + B oc-ON  + E t3N ------------- ^  B o c - N ^ > ~ O H
6 H 80 °C  H „  H
89%
c h 3
H3C - C - 0 ~ C 0 — Boc- 
CH3
Scheme 2.3.1.2 Boc group protection of aminophosphonous acid.
J v . P  10% NaoCCK P
H2N ^ P - O H  + Z-OSu - 0 /  —— .  Z -N  P " 0 H
c h 3o c h 2c h 2o c h 3 12
o
/  \  H2 11
^  j j  C - O - C —  z  group
Scheme 2.3.1.3 Z group protection o f aminophosphonous acid.
In the activation and coupling of carbamate-protected amino acids, it is known the 
carbamate carbonyl can participate by cyclizing onto the activated carboxylate carbonyl 
(oxazalone formation) . 4 8  Because of the possibility for similar participation of the 
carbamate group in phosphinate amino acid activation and coupling (see Chapter 3 for 
details), we wished to prepare amino protected derivatives that could not provide such
23
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anchiomeric participation. The triphenylmethyl (trityl) group is the one we chose here.
Dde5 0  groups (Fig. 2.3). Compound 5 (prepared as in Scheme 2.1.1) was treated with 
triethylammonium bicarbonate (TEAB) at room temperature to cleave selectively the 
trimethylsilyl protection without removing the trityl group (Scheme 2.3.1.4). The TEAB 
work-up allowed isolation of the triethylammonium salt of the phosphinate 13. which 
was organic soluble. Attempted isolation of the free acid of 13 always led to significant 
detritylation.
Others include a variety of sulfonyl groups , 4 9  and vinylogous imide protection like the
S—NH
Nbs Bts
0
S e s Dde
Fig. 2.3 Non-participated protecting groups.
p S iM e3
N )S iM e 3 H H O  Et3NH 
135
Scheme 2.3.1.4 Preparation o f trityl-protected aminophosphonous acid.
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Another non-participating-protected aminophosphonous acid, 
(phthalimidomethyl)phosphonous acid, was prepared by reaction of bis(trimethylsilyl) 
phosphonite 441 with (bromomethyl)phthalimide (Scheme 2.3.1.5)j0.
O 0
(Me3SiO)2PH
Scheme 2 J.1.5 Preparation of (phthalimidomethyl)phosphonous acid.
2.3.2 Protection of Phosphonous Terminal
The vast majority of phosphonous protecting groups merely serve to prevent a reaction 
between the acidic phosphinate hydrogen and basic reagents. Consequently many of the 
protecting groups used for phosphinate protection are identical to carboxylate protecting 
groups in terms of introduction and cleavage.
The esterification of yV-protected aminophosphonous acids with alcohols in the 
presence of 1,3-dicyclohexylcarbodiimide (DCC) and 4-(dimethylamino)pyridine 
(DMAP) in dichloromethane (DCM) 3 1 generated Fmoc-protected phosphonite esters. 
Instead of DCC and DMAP, l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide 
hydrochloride (EDC) can be used as coupling reagent. The mixture was stirred at room 
temperature. The solution was diluted with EtOAc, washed with saturated KH2 PO4 , 
saturated NaHCC>3 , and brine, dried over Na2S 0 4, and evaporated to give peptide P(III) 
analogs. The EDC method has a better workup procedure than that of DCC/DMAP 
method. Use of the water-soluble carbodiimide proved to be important in facilitating the
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reaction workup, since silica gel chromatography could be avoided. The yields o f both 
methods were about the same.
1 .R 2OH
X 2. DMAP3. DCC
£   ►
H' H h ' 0H ° r EDC
X p
H
14: R ^F m oc; R2=allyl 
15: R,=Fmoc; R2=Bn 
16: R ^B o c; R2=/Bu 
17: R ^B o c; R2=Bn
18: R,=Z; R2=allyl 
19: Ri=Z; R2=neopentyl 
20: R1=Z; R2=CHPh2 
21: Rt=Z; R2=(Bu 
22: R^trityl; R2=allyl
Scheme 2.3.2 Esterification of aminophosphonous acid and alcohols with DCC/DMAP.
2.4 Experimental Material 
General Information
All reactions were performed in dry glassware under nitrogen or argon. Dichloromethane, 
toluene and triethylamine were refluxing over CaH 2 and then distilling directly onto dry 
molecular sieves. THF was refluxed over Na-benzophenone and distilled just prior to 
use. Anhydrous pyridine, methanol, benzyl alcohol and DMF were purchased from 
Aldrich. Dichlorotriphenylphosphorane was stored and proportioned in a strictly 
anhydrous environment (dry argon box). Triethylammonium bicarbonate (TEAB) was 
prepared by bubbling C 0 2  (dry ice) into a stirred suspension of 87 mL water and 8.7 mL 
triethylamine until all base was in solution (0.75 M) and the pH was at 8.5. NMR spectra 
were collected on Bruker AC-200 and AC-250 FT NMR spectrometers, and were 
referenced either to internal tetramethylsilane (*H) or external H 3 P 0 4  (3 tP). Coupling 
constant (J) are given in Hz. Melting points were performed on a Fisher Meltemp. FAB
26
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
MS was performed on a Finnigan MAT-900 double sector mass spectrometer equipped 
with a PATRIC detector or a VG 7070E-HF using nitrobenzyl alcohol (NBA) or glycerol 
as the matrix. Column chromatography procedures utilized silica gel (Merck, 230-400 
mesh).
Tritylamine:52
It was prepared by stirring solid trityl chloride (30 g; 0.108 mol) with an excess of conc. 
Aqueous ammonia (28%, 150 ml; 2.22 mol) at room temperature for 2 days. The white 
solid formed was collected by suction filtration, dissolved in 500 ml ether, washed with 
10% NaHCC>3 (2 x 150 mL) and dried (Na2 S 0 4). The solvent was evaporated and the 
product was dried under high vacuum. Yield: 16.8 g (71%). mp 95 °C, (lit. 5 2  mp 96 °C) 
'H  NMR (250 MHz, CDCI3) 8  2,26 (br s, 2H, NH2), 7.26 (s, 15H, 3Ph). 
A-Trityl-2-methylpropanimine (2):52
A mixture of tritylamine 1 (13.0 g; 0.05 mol), anhydrous EtOH (50 mL), and 
isobutyraldehyde (4.0 g; 0.055 mol) was heated to reflux overnight. The solvent was 
evaporated to give a practically pure product, which was recrystallized from 
benzene/hexanes. Yield: 13.6 g (82%). mp 89 °C, (lit. 5 2  mp 88-90 °C). lH NMR (250 
MHz, CDClj) 5 1.13 (d, 6 H, 2 CH3), 2.61 (m, 1H, CH(CH3)2), 7.30 (m, 15H, 3 Ph). 
Ammonium phosphinate (3):39
49% aqueous solution of hypophosphorous acid (13.2 g, 0.2 mol) was added to 0.88 M 
aqueous ammonia (7.7 g, 0.22 mol) for 1 hr. Water was removed with rotary 
evaporation. The white crystals were dried under high vacuum. Yield: 16.3 g (98%). 3lP 
(101 MHz, CDC13) 8  4.35; mp 138 °C, (lit. 3 9  mp 138-139 °C).
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Bis(trimethylsilyl) phosphonite (4):41
This was prepared by heating together ammonium phosphinate 3 (2.5 g, 30 mmol), 8  mL 
dried THF and 1,1,1,3,3,3-hexamethyldisilazane (4.8 g, 30 mmol) at 100-110 °C under 
nitrogen for 5 hr in a 2-neck flask fitted with a septum and condenser. 3IP (101 MHz, 
CDCI3 ) 8  137.6.
l-Amino-2-methylpropanephosphonous acid (6):39,40 
Method A:40
THF (15 mL) was added from a syringe to the in situ generated bis(trimethylsilyl 
phosphonite 4 (30 mmol) at 0 °C under N2  and stirring was continued for 5 min. A 
solution of AT-trityl-2-methylpropanimine 2 (9.4 g, 30 mmol) in CHC13 was then gradually 
injected at 0 °C and stirring for 12 hr gave the silylated, tritylated aminophosphinate 5 
(31P (101 MHz) 5 152.5). The solvent was removed under reduced pressure, and the 
residue was dissolved in 1 M HC1 in MeOH (50 mL) and refluxed for 15 min. The 
solvent was again removed under reduced pressure. Water (50 mL) was added and the 
mixture was extracted with diethyl ether (3 x 20 ml). The aqueous layer was evaporated 
under reduced pressure. The residue was dissolved in anhydrous EtOH (50 mL) and 
treated with an excess of propylene oxide. The precipitated product was isolated by 
suction, washed with EtOH and dried under vacuum. Yield: 2.46 g (57%). 'H  NMR 8  
(250 MHz, D 20 )  1.09-1.13 (2 d, /=  7.0, 6 H, CH(CH3)2), 2,26 (m, 1H, CH(CH3)2), 2.95 
(m, 1H, CH(C 3H7)), 7.10 (d, / PH=535, IH, P-H); 3lP NMR (101 MHz, CDCl3) 8  14.1; 
Analysis cal’d  for C4 H 1 2N0 2 P: C, 35.02; H, 8.82; N, 10.23; found; C, 35.11; H, 8.70; N, 
10.23.
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Method B:39
The diphenylmethylaminophosphonous acid 8  (14.5 g, 0.047 mol) was heated together 
with an excess of 49% hydrobromic acid ( 6 8  g) at 100 °C for 2 h until two distinct phases 
had separated. The mixture was evaporated to dryness under reduced pressure and the 
residue taken up in water. The aqueous solution was washed several times with ether to 
remove diphenylmethyl bromide and then evaporated to dryness. The residue was 
dissolved in EtOH and propylene oxide added dropwise until precipitation started. The 
solid was then filtered off, washed with EtOH and then ether, and dried. Yield: 6.4 g 
(46%).
(Diphenylmethyl)ammonium hypophosphite (7) : 39
It was prepared by mixing equimolar amounts of diphenylmethylamine (18.3 g, 0.1 mol) 
and anhydrous hypophosphorous acid (6 . 6  g, 0.1 mol) in EtOH (35 mL) for I h. 
l*(Diphenylmethyl)amlnophosphonous acid (8):39
Equimolar amounts of diphenylmethylammonium hypophosphite 7 (0.1 mol) and 
isobutyraldehyde were dissolved in absolute EtOH (20 mL), and the mixture was heated 
to reflux for 3 h. On cooling of the solution a precipitate of the 
diphenylmethylaminophosphonous acid formed, and this was filtered off, washed with 
EtOH, then ether, and dried. Yield: 14.5 g (48%).
1-Amino-ethanephosphonous acid (9):39
Acetaldehyde (4.4 g 0.1 mol) in water (25 mL) was added dropwise to a refluxing 
solution of diphenylmethylamine hydrochloride (22 g, 0.1 mol) and 50% aqueous 
hypophosphorous acid (13.2 g, 0.1 mol) in water (50 mL). Heating was continued for 2 
h, after which the solution was cooled and the solid filtered off, washed with acetone, and
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dried to give 19.2 g (42%) o f a white solid. lH NMR 8  (250 MHz, D 20 )  1.35-1.44 (2d, 
7=7.5-15, 3H, CHCH3), 2,24 (m, 1H, CH(CH3)2), 6.96 (d, 7PH=530, 1H, P-H); 31P NMR 
(101 MHz, D20 )  8  21.2; FAB-MS m/e 108.4 (M+H)+.
l-[N-(9-Fluorenylmethoxycarbonyl)amino]-2-methylpropanephosphorous acid 
(10):45
Compound 6 (2.4 g, 17.5 mmol) was dissolved in water (17.5 mL), the pH of the solution 
was adjusted to 9.5 with 4 N NaOH and the mixture cooled to 4 °C. Fmoc-Cl (4.98 g
19.3 mmol) in dioxane (17.5 mL) was added. The mixture was stirred for 6  h while the 
pH was maintained at 9-9.5 by periodic addition of 4 N NaOH. Then the mixture was 
allowed to warm to room temperature and washed with ether (30 x 3 mL). The aqueous 
solution was slowly added to a solution o f 6  N HC1 (70 mL) at 0 °C. The solid product 
was collected by filtration and dried under vacuum. Yield: 5.8 g (92%). ‘H NMR (250 
MHz, DMSO-t/e) 8  0.91-1.09 (2d, 6 H, 7=5.0, CH(CH3)2), 2.05 (m, 1 H, CH(CH3)2), 3.43 
(m, 1H, CHCH(CH3)2), 4.31 (3H, CHfluorenyi + CH2), 6.72 (d, 7=475, PH), 7.36 (m, 
2 H f l UOreny i)»  7.74 (m, 2 H n uore„ y i ) ,  7.89 (m, 2 H n u oren y i) ;  3IP (250 MHz, DMSO-76) 8  28.0; 
FAB-MS m/e 360.1 ((M+H)+); Analysis cal’d for Ci9H2 2 N0 4 P: C, 63.49; H, 6.17; N, 
3.90; found: C, 63.05; H, 5.94; N, 4.04.
l-[iV-(/-Butoxycarbonyl)amino]-2-methylpropylphosphonous acid (11):
A mixture o f l-amino-2-methylpropyIphosphonous acid (2.55 g. 15 mmol), Boc-ON 
(4.10 g, 16.6 mmol), TEA (3.13 mL, 22.2 mmol) and DMF (4.5 mL) was heated at 70 °C 
for 12 h. The triethylamine and DMF were removed under high vacuum and the oily 
residue was diluted with water (65 mL), and the pH was adjusted to 7.5 by addition of 4N 
NaOH. The aqueous layer was washed with EtOAc (4 x 30 mL), then was acidified to 
pH I with 12 N HC1 and extracted with CHC13. The combined CHC13  layers were dried
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over Na2 SC>4 and concentrated in vacuo to form l-[/V-(/-butoxycarbonyl)amino]-2- 
methylpropylphosphonous acid as yellow oil. Yield: 3.09 g, 89%. *H NMR (250 MHz, 
CDCl3) 1.05 (m, 6 H, CH(CH3)2, 1.45 (s, 9H, COO-rBu), 2.22 (m, IH, CH(CH3)2), 3.79 
(m, 'H, CH(C 3H7» , 4.97 (d, 7 NH= 1 0 . 0  Hz, IH, NH), 7.04 (d, 7PN=560 Hz, 1H, P-H); 31P 
NMR (101 MHz, CDC13) 28.6, 29.7 (7p.o h =11 1  Hz). 
l-[iV-(Benzoxycarbonyl)amino]-2-methylpropylphosphonous acid (12):47 
l-Amino-2-methylpropanephosphonous acid (0.14 g, 1 mmol) was dissolved in 10% 
Na2C 0 3 (5 mL). Z-OSu (0.374 g, 1.5 mmol) in dimethoxyethane (3 mL) was slowly 
added at room temperature. The mixture was stirred overnight, the dimethoxyethane 
removed under reduced pressure, followed by adjusting pH to 7.5. The aqueous layer 
was washed with ethyl acetate ( 5 x 3  mL). HC1 was used to adjust pH to 1.5. Then the 
aqueous layer was extracted with chloroform ( 5 x 3  mL). The organic layer was dried 
over M gS04, and evaporated to get a white solid product. Yield: 0.26 g, 96%. lH NMR 
(250 MHz, CDC13) 8  0.89-1.10 (2d, 6 H, CH(CH3)2), 2.23 (m, IH, CH(CH3)2), 3.90 (m, 
IH, CHCH(CH3)2), 5.36 (brs, IH, NH), 7.00 (d, 7=562, P-H); 31P (101 MHz, CDCI3) 5 
30.9,31.7.
l-[(Trityl)amino]-2-methylpropanephosphonous acid triethylammonium salt(13):
The residue of intermediate 5 (1 mmol) was taken up in TEAB (1 M, 20 mL). The 
mixture was stirred for 3 h. The solution was extracted with CH 2C12  (3 x 20 mL), and the 
organic phase was dried under reduced pressure. Yield: 2.3 g (95%). 'H  NMR (250 
MHz, CDC13) 8  0.83-1.27 (m, 6 H, 2CH3), 2.52 (m, IH, CH(CH3)2), 2.99 (2d, 7=7, IH, 
CHPO), 6.48 (d, 7=525, IH, P-H), 7.22 (m, 15H, 3Ph), 7.57 (d, 7=7, IH, NH); 31P (101 
MHz, CDC13) 8  27.5; FAB-MS (NBA) m/e 377.9 (M-H)\
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(Phthalimldomethyl)phosphonousacid:30
Ammonium phosphinate 3 (0.42 g, 5 mmol) and hexamethyldisilazane (1.11 ml, 5.3
mmol) were heated together at 100-110 °C under nitrogen for 2 h in a 3-neck flask fitted
with a septum and a condenser. The system was cooled to 0 °C and dry DCM (5 mL) was
injected, followed by (bromomethyl)phthalimide (1.26 g, 5.3 mmol). The reaction was
stirred overnight at room temperature, Filtered, and the solvent was removed in vacuo to
yield an oil. This oil was dissolved in 8  mL methanol to achieve desilylation and
dissolution. This solution was crystallized overnight, filtered and the resulting solid was
dried in vacuum to give the phosphorous acid (0.932 g, 78%). ‘H NMR (250 MHz,
CDCI3 ) 5 5.52 (d, 2H, 7=10.75, C H 2), 7.13 (d, 7=567, P-H), 7.80 (m, 2H, Ph), 7.93 (m,
2H, Ph); 3lP (101 MHz, CDCI3) 5 21.7; FAB-MS (glycol) m/e 224.2 (M -H)\
O-Allyl {l-[A-(9-fluorenylmethoxycarbonyl)amino]-2-methylpropane}phosphonite
(14):
To a solution of compound 9 (0.7 g. 1.95 mmol) and allyl alcohol (0.122 g, 2.1 mmol) in 
dry CH2 CI2  (3.5 mL) at room temperature under nitrogen, was added DMAP (0.135 mg,
1.1 mmol) and DCC (0.444 g, 2.15 mmol). After stirring at room temperature for 12 h, 
the mixture was diluted with EtOAc (35 mL), filtered and washed and successively with 
5% KHSO4 , saturated NaHC0 3  and saturated NaCl solution, dried over Na2S04 and 
evaporated to give a white solid (0.62 g, 80%). *H NMR (250 MHz, CDC13) 8 0.89-1.10 
(2 d, 6H, CH(CH3)2), 2.25 (m, IH, CH(CH3)2), 3.92 (m, IH, CHCH(CH3)2), 4.24 (m, IH, 
CHfiuorenyi), 4.45-4.64 (4H, CH2fiuorenyi + CH2CH=CH2), 5.00 (brs, IH, NH), 5.31 (m, 2 H, 
CH2CH=CH2), 5.88 (m, IH, CH=CH2), 7.05 (d, 7=550, P-H), 7.34 (m, 4Hnuore„yi), 7.50 
(m, 2Hfiuorenyi)> 7.68 (m, 2Hn„orenyi); 31P (101 MHz, DMSO-de) 8 31.9; FAB-MS (NBA) 
m/e 400.1 (M+H)+.
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0-Benzyl {l-[Ar-(9-fluorenylmethoxycarbonyl)amino]-2-methyl}propanephosphonite
(IS ):5'
To a solution of compound 9 (1.4 g. 3.9 mmol) and benzyl alcohol (0.42 mL, 4.3 mmol) 
in dry CH2C12  (5 mL) at room temperature under nitrogen, was added DMAP (48 mg, 
0.39 mmol) and DCC (0.889 g, 4.3 mmol). After stirring at room temperature for 12 h, 
the mixture was diluted with EtOAc (40 mL), filtered and washed and successively with 
5% KHSO4 , saturated NaHCC>3 and saturated NaCl solution, dried over Na2S04 and 
evaporated to give the ester. Yield: 1.52 g (87%). ’H NMR (250 MHz, CDCI3) 8 0.88- 
1 . 2 1  (2 d, 6 H, CH(CH3)2), 2.19 (m, IH, CH(CH3)2), 3.36 (m, IH, CHCH(CH3)2), 4.34 
(3H, CHfiuorenyi + CH2), 5.06 (m, 2H, CH 2Ph), 5.10 (m, NH), 6.97 (d, 7=557, P-H), 7.31 
(m, 4Hfluorenyl)> 7.72 (m, 2Hnuorenyl)< 7.85 (m, 2Hnuorenyl)> P (101 MHz, DMSO-7fi) 8
33.4, 33.7; FAB-MS (NBA) m/e 450.2 (M+H)+; Analysis cal’d for C26H28N0 4 P: C, 
69.46; H, 6.28; N, 3.12; found: C, 69.92; H, 5.98; N, 3.30.
0-f-ButyI {l-[iV-(r-butoxycarbonyl)amino]-2-methylpropane}phosphonite (16):st
Prepared according to esterification procedure for 15 using 1 -[N-(t- 
butoxycarbonyl)amino]-2-methylpropylphosphonous acid (0.36 g, 1.5 mmol) and r-butyl 
alcohol (0.17 ml, 1.7 mmol) to yield 16 (0.31 g, 72 %). lH NMR (250 MHz, CDC13) 8  
0.99-1.09 (2d, 6 H, CH(CH3)2), 1.45 (s, 9H, 9H,.bulyl), 1.50 (s, 9H, 9H Boc), 2.21 (m, IH, 
CH(CH3)2), 3.78 (m, IH, CHCH(CH3)2), 4.63 (brs, IH, NH), 7.20 (d, 7=538, P-H); 3,P 
(101 MHz, CDC13) 8  24.2,24.9.
0-Benzyl {l-[/V-(f-butoxycarbonyl)amino]-2-methylpropane}phosphonite (17):SI 
Prepared according to esterification procedure for 15 using l-[N-(r- 
butoxycarbonyl)amino]-2-methylpropylphosphonous acid (83 mg, 0.35 mmol) and 
benzyl ester (0.04 mL, 0.4 mmol) to yield 17 (80 mg, 77 %). lH NMR (250 MHz,
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CDCl3) 8  0.99-1.10 (2 d, 6 H, CH(CH3)2), 1.43 (s, 9H, 9HBoc), 2.24 (m, IH, CH(CH3)2), 
3.88 (m, IH, CHCH(CH3)2), 4.88 (d, IH, NH), 5.12 (m, 2H, CH 2 Ph), 7.03 (d, 7=550, P- 
H); 3lP (101 MHz, CDC13) 5 31.2, 32.3 (7P^ = 1 1 1  Hz)..
O-Allyl {l-[Ar-(Benzoxycarbonyl)amino]-2-methyIpropane}phosphonite (18):
Prepared according to esterification procedure for 15 using EDC instead of DMAP/DCC, 
starting from l-[/V-(benzoxycarbonyl)amino]-2-methylpropylphosphonous acid (0.1 g,
0.4 mmol) and allyl ester (0.3 mL, 0.44 mmol) to yield 18 (67 mg, 54 %). *H NMR (250 
MHz, CDC13) 6  0.89-1.10 (2d, 6 H, CH(CH3)2), 2.23 (m, IH, CH(CH3)2), 4.01 (m, IH, 
CHCH(CH3)2), 4.52 (m, 4H, CH2CH=CH2), 5.10 (s, 2H, CH 2 Ph), 5.27 (m, 2H, 
CH 2CH=CH2), 5.36 (br s, IH, NH), 5.88 (m, IH, CH=CH2), 7.05 (d, 7=542, P-H), 7.33 
(s, 5H, Ph); 31P (101 MHz, CDC13) 5 34.1,34.3, 34.7, 35.1.
0-t-Butyl {l-[iV-(Benzoxycarbonyl)amino]-2-methylpropane}phosphonite (21): 
Prepared according to esterification procedure for 15 using EDC instead of DMAP/DCC, 
starting from l-[/V-(benzoxycarbonyl)amino]-2 -methylpropylphosphonous acid (0 . 1  g,
0.4 mmol) and r-butyl ester (33 mg, 0.44 mmol) to yield 21 (50 mg, 38 %). lH NMR 
(250 MHz, CDCb) 50.89-1.10 (2d, 6 H, CH(CH3)2), 1.45 (s, 9H,.butyI), 2.23 (m, IH, 
CH(CH3)2), 3.88 (m, IH, CHCH(CH3)2), 5.10 (s, 2H, CH 2 Ph), 5.38 (brs, IH, NH),
7.13(d, 7=542, P-H), 7.33 (s, 5H, Ph); 31P (101 MHz, CDC13) 5 23.5,23.9,24.4, 25.1. 
O-Neopentyl {l-[/V-(Benzoxycarbonyl)amino]-2-methylpropane}phosphonite (19): 
Prepared according to esterification procedure for 15 using EDC instead of DMAP/DCC, 
starting from l-[iV-(Benzoxycarbonyl)amino]-2-methylpropylphosphonous acid (0.1 g,
0.4 mmol) and neopentyl ester (39 mg, 0.44 mmol) to yield 19 (85 mg, 62 %). [H NMR 
(250 MHz, CDCI3 ) 5 0.92-1.10 (m, 15H, 9Hf.butyl+CH(CH3)2), 1.88 (m, IH, CH(CH3)2),
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3.60-3.81 (m, 2 H ne0pe n ty i ) ,  4.04 (m, IH, C H C H ( C H 3) 2) ,  4.86 (brs, IH, N H ) ,  5.12 (s, 2 H, 
C H 2 P h ) ,  7.04(d, 7=547, P - H ) ,  7.34 (s, 5H, Ph); 31 P  (101 MHz, C D C I 3 )  8  34.5,34.8, 35.2,
35.4.
O-Benzhydryl {l>[^V*(Benzoxycarbonyl)amlno]*2>methylpropane}phosphonite (20): 
According to esterification procedure from 1 5  using EDC instead of DMAP/DCC, 
starting from l-[vV-(benzoxycarbonyI)amino]-2-methylpropylphosphonous acid (0.1 g,
0.4 mmol) and benzhydryl alcohol (81 mg, 0.44 mmol) to yield 20 (57 mg, 38 %). ‘H 
NMR (250 MHz, CDC13) 5 0.88-1.10 (2d, 6 H, CH(CH3)2), 1.88 (m, IH, CH(CH3)2), 3.98 
(m, IH, CHCH(CH3)2), 4.86 (brs, IH, NH), 5.09 (s, 2H, CH 2Ph), 5.85 (m, IH, CHPh2), 
7.28(2d, 7=405, P-H), 7.34 (s, 15H, 3Ph); 3lP (101 MHz, CDC13) 8  31.2, 31.7,32.6. 
O-Allyl {l-[(Trityl)amino]-2-methylpropane}phosphonite (22) : 31 
Compound 1 3  (1.1 g, 2.9 mmol) and allyl alcohol (0.22 mL, 3.2 mmol) were dissolved in 
CH2 C12  (20 mL). DMAP (35 mg, 0.29 mmol) and then DCC (0.63 g, 3.0 mmol) were 
added to the solution, and the mixture was stirred for 15 h, and diluted with EtOAc (35 
mL), filtered and washed successively with 5% KHSO4 , saturated N aH C03. and NaCl 
solutions, dried over Na2 SC>4 and evaporated to give the crude phosphonous monoester, 
which was purified by flash column chromatography (acetone-hexane 1:2, Et3N 0.5%). 
Yield: 0.80 g (6 6 %). 'H  NMR (250 MHz, CDC13) 8  0.83-1.37 (m, 6 H, 2CH3), 2.56 (m, 
IH, CH(CH3)2), 2.81 (2d, IH, CHPO), 4.35 (m, 2H, CH2CH=CH2), 5.28 (m, 2H, 
CH 2CH=CH2), 5.85 (m, IH, CH=CH2), 7.24 (m, 15H, 3Ph); 3lP (101 MHz, CDC13) 8  
40.0; FAB-MS (NBA) m/e 377.9 (M-H)\
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CHAPTER 3. SYNTHESIS OF PHOSPHONOPEPTIDE ANALOGS 
BY USING ONE-POT PROCEDURE
3.1 Solid-Phase Synthesis
Methods for synthesizing peptides are divided into two categories: solution (classical) 
and solid-phase (SPPS). The classical methods have evolved since the beginning of the 
20th century. The solid-phase procedure was first proposed by R. B. Merrifield in 1962, 
with a full paper published in 1963.33 Solution synthesis retains value in large-scale 
manufacturing, and for specialized laboratory applications. However, the need to 
optimized reaction conditions, yield, and purification procedures for essentially every 
intermediate render the classical methods time consuming and labor-intensive. 
Consequently, most workers now requiring peptides for their research opt for the more 
accessible solid-phase approach. The essential advantage of SPPS is the ease with which 
the blocked intermediates are separated from staring materials, reagents and most of the 
by-products. The separation processes are quick and simple, and can be machine-aided. 
There is an enormous time and labor advantage over the corresponding operations in 
solution chemistry which commonly involve techniques of solvent extraction, filtration, 
evaporation, and crystalization. Retention of the resin-bound peptide in the same reaction 
vessel at all the time also minimizes physical losses. Because soluble reagents can be so 
easily removed by filtration, large excesses can be used, encouraging high efficiency in 
the various chemical steps.
The concept o f SPPS has been outlined in Scheme 3.1. An N-protected amino acid, 
containing appropriate side-chain protection if needed, is attached to a solid support. The 
temporary N-protecting group is then removed and the amino acid-support is thoroughly
36
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washed with solvent. The next N-protected amino acid is then coupled to the amino acid- 
support. The coupling may also be carried out using peptide fragments instead of single 
amino acids, where the peptide fragment is N-terminal and side-chain protected. After 
this reaction is completed, the dipeptide-support is washed with solvent. The 
deprotection /  coupling cycle is repeated until the desired sequence o f amino acids is 
generated. The peptide-support is cleaved to obtain the totally deblocked peptide.
H I M 
P ro t-N -C H -C -O HC H -c-O H  + HO—(su p p o rt
j  attach to support
P ro t-N -C H -C -O — support
j  deprotection
H g N -C H -C -Q -( support
|  couple
P ro t-N -C H -C -H N -C H -C -Q -{ support
1 repeat deprotection an d  couple
HN-CH -C-O — support 
1 |  Cleave from support
+ [support
Scheme 3.1 General approach to solid-phase peptide synthesis.
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Ideally, the cleavage reagent also removes the amino acid side chain protecting 
groups, which are stable to the deprotection reagent. These steps may be carried out as 
either a batch process, where the support is filtered between each step, or as a continuous 
flow process, where the support is always solvated during reagent exchange.
3.2 SPPS with Amino Phosphonites
Our laboratory has previously reported a method for synthesizing phosphonate esters 
and phosphonamide peptide analogs . 3 7  In this scheme, the amino-phosphonous acid 
esters were activated with dichlorotriphenylphosphorane (Ph3PCl,) to produce a reactive 
trivalent species, which was used in the coupling step with an alcohol or an amine 
(HXRj) to provide phosphonites. The phosphorus [P(IH)] tripeptide analogs were then 
oxidized or sulfurized to the desired phosphonates or phosphonamides (Scheme 1.4).
Given the success o f this method in solution, it was expected to be even more 
efficient in solid-phase for the reactions just mentioned in section 3.1. Our strategy for 
solid-phase synthesis of phosphonopeptide and thiophosphonopeptide CPA inhibitors is 
shown in Scheme 3.2.1. Since effective CPA inhibitors have a free carboxylate at the 
C-terminus, we will attach the first residue of the phosphonopeptide to a hydroxy resin. 
That will generate a free acid after final cleavage. CPA best recognizes substrates and 
inhibitors that have a hydrophobic aromatic group on the side chain (Phe, Trp) of the C- 
terminal residue. Additional, here we wish to make a phosphonate ester bond, so the first 
residue is not an amino acid, but rather an a-hydroxyl acid, L-phenyllactic acid, O- 
protected with a Fmoc moiety 23. After deblocking of the resin-bound Fmoc-carbonate 
24, the free hydroxyl group on the resin will be coupled to phosphonochloridite 25 
(generated according to our previously published procedure37) to give resin-bound 
phosphonite 26. This is then immediately oxidized or sulfurized to give solid-supported
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phosphonate 27. It was expected that Fmoc-protected amino of 27 could be elaborated 
by normal Fmoc peptide synthesis protocols to give phosphonopeptide after cleavage 
from the support.
HO
Fmoc-O'
BnVH
o
Bn Bn
Fmoc-O'
J l . O ' ^  20% piperidine/ DMF ^ L . 0
1 T  — H0 T
o
23 24
R1 O
Fmoc-HN^RC°V^O 
'R0  X In
27
R1
F m o c -H N ^ P " CI
OR'
25
[O] or [S] I n  Jl
■     Fmoc-HN P" V o
1 h OR' In
1.20%  piperidine in DMF
2. Fmoc-Phe-OH/ HBTU/ HOBt 
3.20%  piperidine in DMF
4. Z-OSu, DIEA
5. TFA/ phenol/ triisopropylsilane
26
O R 1 0  
Z-HN
<feX in X = O o r S
Scheme 3.2.1 Solid-phase peptide synthesis phosphono and thiophosphono peptide 
strategy.
Several subtler features of this strategy are worthy of comment. First, it is known that 
phosphonate mono esters are generally stable to moderately strong acids like TFA , 3 4  
whereas phosphonamides are highly acid labile. 12 Also, phosphonate ester protecting
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groups like methyl are cleaved by TFA as well. 3 5  Thus in picking our resin and our ester 
group R’ on the phosphinate amino acid we chose one that were compatible with a 
general SPPS strategy employing a TFA-labile support, and TFA labile “side-chain” 
protection. In this case, since we needed a C-terminal acid, we chose the trifluoroacetic 
acid (TFA)-labile, p-alkoxybenzyl resin, 4-hydroxymethylphenoxyacetic acid- 
polyethyleneglycol-polystyrene (PAC-PEG-PS, Fig. 3.2.1). This PEG-PS graft resin has 
several advantages over traditional PS resin as it solvates (“swells”) well in a wide range 
of solvents and as a result has physical properties that tend improve peptide synthesis. 
Furthermore, the choice of Fmoc strategy allows for simply spectrophotometic assays5 4  
for determining coupling yields by analysis of the Fmoc group after cleavage (Scheme 
3.2.2).
Scheme 3.2.2 Spectrophotometric assay5 4  for determining coupling yields by analysis o f 
the Fmoc group. X =301 nm, e = 7800 M 'lcm*1.
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OP A C -P E G -@
Fig. 3.2.1 Solid supports for peptide synthesis.
Our first target for solid-phase phosphonate peptide synthesis was the known 
potent CPA inhibitor phosphonotripetide la  and its previously unknown 
thiophosphonopeptide analog lb. Preparation of Fmoc-protected a-hydroxyl acid is 
illustrated in Scheme 3.2.3. Esterification of L-3-phenyllactic acid with methanol in the 
presence of H 2 SO4  led to ester L-3-phenyllactic acid methyl ester 28a.55 Protection of 
hydroxyl functionality with Fmoc-Cl in pyridine5 6  provided the compound 29, which 
after acid hydrolysis gave the desired Fmoc-hydroxy acid 30.
HO C 0 2H
Bn Bn
1  c h 3 o h /h 2 s o 4  T
HO C 0 2CH; 
28a
Fmoc-Cl/ Pyridine
Bn
F m o c - O ^ C 0 2H
30
Bn
HCI/ dioxane Jk.
Fmoc-O C 0 2CH3 
29
Scheme 3.2.3 Preparation o f Fmoc-protected a-hydroxy acid.
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The results o f solid-phase phosphonopeptide synthesis strategy according to Scheme
3.2.1 are given below. First, loading Fmoc protected a-hydroxy acid 30 to the solid 
support was accomplished by double coupling in the presence of I-(2 - 
mesitylenesulfonyl)-3-nitro-l,2,4-triazole (MSNT) and 1-methylimidazole (Melm) 
(Scheme 3.2.4) . 5 7  The final loading was 0.17 mmol/g (87%).
Bn
T HO 
F m o c-O  C 0 2H — Fmoc
30
M SN T/M elm
Bn
A°
23
MSNT:
0. N ^ N°2
“ N A
Melm:
Scheme 3.2.4 Loading Fmoc-protected hydroxy acid to resin.
Next the aminophosphinate (10 equivalents, relative to resin-bound a-hydroxy acid), 
which was activated by PI13PCI2  (1.5 equivalents) in a solution of DCM was transferred 
to an existing resin-bound oligomer containing alcoholic nucleophile 24 (in this case is 
a-hydroxy acid) for 1 hr 45 minutes to provide resin-bound phosphonitopeptide 26. 
After coupling, extra reagents were washed away by DCM ( 3 x 3  ml) and DMF ( 3 x 3  
ml) and dried in vacuum.
Oxidation o f species 26 on-resin with an oxygen or sulfur electrophile provided 
the desired phosphonate linkage. Thus, treating with the resin with r-BuOOH led to 
(presumably) formation of resin-bound phosphonopeptide; adding Sg to P(m ) resin gave
42
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thiophosphonate peptide. The coupling yields of the phosphinate amino acid, determined 
by Fmoc UV analysis54, were typically 40%-70%. After removal of the Fmoc group, 
Fmoc-Phe-OH was immediately coupled with HATU/DIEA/DMF for 1 hour. 4 4  
However, Fmoc analysis showed that no Fmoc group was incorporated. Also, after 
addition of Z-OSu and cleavage from the support, none of the desired product was found 
by mass spectral analysis or 31P NMR analysis.
Fm oc-H N ^P'°V ^O  
OR' I n
OwOR'
HN O + 
0  Bn
HO
20% piperidine
base
h2n ' ; p  
•• O '
X
1. Z-Phe-OH / 
HATU/DIEA
2. TFA /  Phenol/ 
Triisopropylsiiiane
*
in H q^ in 
theory MS: 621
Scheme 3.2.5 Formation of 5-keto-3-isopropyl-6-benzyl-l,4,2-oxazaphospholine, a 
phosphorus analog of a diketopiperazine (DKP).
Based on these results we hypothesized that the free amino group of the anchored 
phosphonodipeptide was poised for a base-catalyzed intramolecular reaction on the 
C-terminal carbonyl. This is a common side-reaction in SPPS where dipeptides are 
anchored as esters, caused by base deprotection (Fmoc) or neutralization, resulting in the 
release of a cyclic diketopiperazine (DKP) from the solid support. 5 8 ,5 9  In our case, after
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removal of the protecting group, a stable 6 -membered cyclic 5-keto-3,6 -dialkyl-1 ,4 ,2 - 
oxazaphospholine was generated and ended up in the piperidine deblocking solution 
(Scheme 3.2.5). This was confirmed by evaporating the cleavage solution, and then 
analyzed the solution by 3lP NMR.
Table 3.1 Cleavage methods
Cleavage Reagent
Piperidine
50% in DMF 
50% in DMF 
50% in DCM 
20% in DCM 
20% in DMF 
TBAF (0.1 Ml 
DMF 
DMF 
DMF 
THF 
THF/DMF
Cleavage Time 
(min)
2 .5  
2
2 ,3
2,8
30 Sec x 8
20
3 ,7
2.2.5 
2,2 
2,2
3lP (8 ) o f Solution coupling yield of
(ppm) Fmoc-Phe-OH (%)
9.5 .26  52
22.4.26 39
17.18.5.21.2 47
22.7 47
20.6 44
17,20.5, 25 54
17.20.5 43
20.5 45
20.9.21.2 39
20.6 37
In SPPS many methods have been developed to reduce DKP formation. Various 
methods have been tried, including different cleavage reagents such as 
tetrabutylammonium fluoride (TBAF) , 5 9  and a  shorter time o f deprotection (Table 3.1).
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While some improvement in the coupling yields of the third residue (Fmoc-Phe-OH; 
37-54%) were obtained with the modified Fmoc cleavage conditions (Table 3.2) of the 
phosphonate dipeptide resins, still no desired products could be observed after addition of 
the Z-group and cleavage from the support. Also, 3IP signals around 20 ppm consistent 
with oxazaphospholine were found in all cleavage solutions, which means phosphorous 
compounds were cleaved from the solid supports.
Fig. 3.2.2 2-Chlorotrityl resin.
Alternatively, 2-chlorotrityl resin (Fig. 3.2.2), in place of PAC resin, was chosen 
to prevent “DKP” formation. This is a very acid-labile resin for preparing peptides and 
partially protected peptide fragments. Due to extreme steric hindrance of this resin, the 
formation of piperazines at the dipeptide step is totally suppressed.60 Detachment of 
protected peptides from resin can be accomplished using acetic 
acid/trifluoroethanol/DCM at room temperature for short periods of time. The 
attachment o f the first residue was carried out with 0.6 equivalents (use 2 equivalents of 
NovaSyn TGT 2-chlorotrityl resin) of the Fmoc-protected hydroxyl acid and 4 
equivalents o f diisopropylethylamine stirred for 25 minutes.61 But probably due to the 
high moisture sensitivity o f the resin, which hydrolyzed the Fmoc-protected hydroxy acid 
from the resin, only 5% loading yield was obtained, according to Fmoc analysis. Thus
45
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both because of “DKP” formation, the low phosphinate coupling yields (40-70%), and 
the lack of desired products, we decided to investigate a solution-phase approach to 
synthesize CPA-inhibitor phosphonopeptide analogs.
3.3 Solution-Phase Synthesis of Phosphonopeptide Analogs
3.3.1 Synthesis of Phosphonite Dipeptide Analogs
h2n  p - o h  
2 H
6 ,9
^  O (n Bu)4N0H/Me0H/H2O  ?  Q  
"2" ©  
h c r  ki/N(nBu)4
3 1 ,3 2
Pivaloyl Chloride/Et3N fj
1 .31 o r 32 
2. 0.5 N HCI
1 .Allyl alcohol 
2. DMAP/DCC
31: R1 = iPr; 32: R2 = CH3; 33: R 1 = iPr, R2 = Bn; 
34: R1 = CH3, R2 =  Bn; 35: R 1 = CH3, R2 = CH3: 
36: R1 = iPr.
Scheme 3.3.1.1 Synthesis o f phosphonite dipeptide analogs.
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Since coupling dipeptide phosphonite analogs to hydroxy acid ester (in solution or solid- 
phase) would avoid formation of “DKP” analogs, dipeptide phosphonite analogs were 
prepared. The synthetic approach is described in Scheme 3.3.1.1. Z-group protected 
amino acids were activated by trimethylacetyl chloride,62 then coupled with 
tetrabutylammonium salts of 1-aminophosphonous acids 31 and 32, where were prepared 
by mixing aminophosphonous acids 6 and 9 with an equivalent of tetra-n- 
butylammonium hydroxide.63 The purpose o f making the tetrabutylammonium salts 31 
and 32 was to make the amino acid derivatives soluble in organic solvents like DCM. 
After making dipeptide phosphonous acids, the Z-protected dipeptide analog 33 was 
esterified with allyl alcohol in the presence of DCC/DMAP as for the carbamate- 
protected phosphonous amino acids (Section 3.3.2) to yield dipeptide phosphonite analog 
36. (see Section 4.1 for synthesis of other peptide esters)
Allyl bromide was also used for protecting of hydroxy acid. Allyl bromide and 
DIEA were added to a solution of L-3-phenyllactic acid in CH3CN and allowed to sit 
overnight to provide the hydroxy acid allyl ester 28b (Scheme 3.2.I.2.).
Bn Bn
I Allyl brom ide/ DIEA JL  x
H O ^ X O g H ------------------------   H0
28b
Scheme 3.3.1.2 Synthesis o f L-phenyllactic acid allyl ester.
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3.3.2 Solution-Phase One-pot Synthesis Approach
The phosphonite dipeptide analog 36 was activated with Ph3PCl2 in the presence of the 
base to produce phosphonochloridite 37 (3,P NMR, Fig. 3.3.1), then coupled with a -  
hydroxy acid ester 28b. 31P NMR showed clean conversion to phosphonite 38 (5 136). 
Following the oxidation, the desired product 39 was formed (Scheme 3.3.2.1). After flash 
chromatographic column purification, the tripeptide analog was obtained as shown by 
FAB mass spectral analysis and 31P NMR.
O ^ v - f  N _  W / B a N
\ r ~ \ f  «■*'" \ r ~ \ »
36 h  O-Allyl 3 7  OAllyl
31P : 178.1 A 
Bn
HO C 0 2Allyl, 
Et3N,1.5 h
^-NH O
38
Bn
p - 0 ^ C 0 2Allyl 
OAllyl
31P: 136.7 B
t-BuOOH 
O 1 h
V -N H  O  .
xp h J p - O  c o 2aii»i
OAllyl
39
31P: 2 3 .8 ,2 4 .2  C 
FAB-MS m/e 663.2 (M+H)+
Scheme 3.3.2.1 One-pot synthesis procedure: adding base in the activation step.
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PPM
Fig. 3.3.1 31P NMR spectra: A, activated species phosphonochloridite 37, 8 = 178.1;
B, coupling product 38, 5 = 136.7; C, oxidation product 39 (before 
purification), 8 = 23.5-24.4; triphenylphosphine oxide and its derivative, 8 
= 27.3-35.8 in each spectrum.
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In applying this approach to synthesize phosphonoester peptides 39 we have 
experienced low product yields (5-38%) that were the result of several side reactions 
(Scheme 3.2.2.2, Fig. 3.3.2). We believe that activation in the presence of the base 
generated 37 (Fig. 3.3.2D), but now excess base can promote the cyclization of the 
N-acyl/carbamoyl group onto the phosphorus, generating oxophosphazole derivative 40 
(Fig. 3.3.2E), which was inactive towards coupling with weak nucleophiles like alcohols 
(Scheme 3.3.2.2). This may be the reason that coupling of Fmoc aminophosphonites to 
the resin-bound hydroxyl acid also produced low yields (40-70%) of coupled products. 
We believe that 31P NMR obtained after attempted coupling and oxidation is in fact the 
oxophosphazole 41 and not a phosphonopeptide.
, U I o  P h 3P C I2 /  E t,N  0 1  ( 0 R  (no R X N ) y q
37(D)
31P  NM R: 1 7 7 ,1 7 8 .8
E t3N
R R 1
tBuOOH ) r ° l
T  O R  
R 2 
41(F)
31P  NM R: 34.1
40 (E)
31P  NM R: 1 9 4 .6
Scheme 3.3.2.2 Formation of oxophosphazole derivative.
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Fig. 3.3.2 31P NMR spectra: D, activated species phosphonochloridite 37, 8 = 177.
178.8; E, formation of cyclic phosphorus species 40, 8 =  194.6; F, 
oxophosphazole derivative 41, 8 =  34.1; triphenylphosphine oxide and its 
derivative, 8 = 27.9-35.1 in each spectrum.
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In an attempt to avoid side reactions caused by extra activation reagent and to 
simplify purifcation o f phosphonopeptide products, resin-bound Ph3PCl3 was prepared 
according to a modified literature procedure.64 The resin-bound Ph3P was swelled in 
dichloromethane, and a solution of triphosgene was added whilst cooling to maintain the 
temperature (Scheme 3.3.2.3). Gel-phase 3,P NMR showed dichlorphosphorane 42 (8
58.3 ppm).
Cl '— '
42
Scheme 3.3.2.3 Preparation of resin-bound dichlorophsphorane.
Due to the high sensitivity towards atmosphere, resin-bound Ph3PCl3 was 
prepared and used in situ. A solution o f Fmoc aminophosphonite 15 and triethylamine in 
DCM was injected into the flask containing resin-bound Ph3PCl3. The 3IP NMR signal of 
the activated species was detected (5 192) ppm, as well as other by-products (5 218, 233, 
234 ppm). However, after coupling with methyl phenyllactate (28a) and oxidation, the 
desired dipeptide was detected (8 25 ppm) with another by-product (5 34 ppm), though 
no improvement on the yield was achieved and the product was contaminated.
A less reactive activation reagent Ph3PF3 was also prepared65 and tested. 
Triphenylphosphine, potassium hydrogen fluoride, and DMF were placed in a NMR tube 
under argon. The solution was cooled, and following the addition of 
diisopropylazodicarboxylate, placed in a sonic bath. 3>P NMR showed clean conversion 
to difluorotriphenylphosphorane 43 (5 55.8 ppm). Also present was a small singlet at 5
52
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25.1, due to triphenylphosphine oxide (Scheme 3.3.2.4). A solution of Fmoc amino 
phosphonite 15 and triethylamine in dichloromethane was injected into the NMR tube. 
But none of the activated species was detected by 31P NMR. This means the PI1 3PF2 43 is 
not strong enough to convert phosphonite to phosphonofluoridite.
In 1997, Professor Hirschmann reported that treatment of the 
phosphonochloridates with tertiary amines prior to addition of the nucleophile resulted 
in the formation of hitherto unrecognized phosphonylation agents, which they formulated 
as phosphonyltrialkylammonium salts 45 .6 6  The latter were more reactive than the 
phosphonochloridates toward both alcohols and amines, affording improved yields o f 
phosphonate esters and amides (Scheme 3.3.2.5.).
1.KHF2,0 ° C
2. DIAD
PPh3 Ph3PF2 43
Scheme 3.3.2.4 Synthesis of Ph3 PFa.
F m o.-H  _ I 0PNB <C0CI)*
: OH
Fmoc—Nv^P^
u 0H ^OPNB Et3N Fmoc—N
O
" OPNB
C-CgHn c-CsHu
44 45
/ I n d o le
HO CONH2
Indole
PNBOv ,0
0  CONH2
c-C6Hh
46
Scheme 3.3.2.S Formation of phosphonyltrialkylammonium salts.
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Ph3p a 2/CH2a 2 et iN(3M)
{  HN—( "  47------------------- -'
Vh v °
n'O-Allyl
36 31PNMR:183.5, 185.4(H)
Bn
48 H O ^C O zA llyl 4g
31P:164.4,166.1 (I) 31 P:173.4,173.5 (J)
t-BuOOH
, p - 0  COgAllylPh
31 P:18.0, 30.1,37.0 31P:76.5-78.1, 94.1 (K)
FAB-MS m / e  621.8 (M-H)‘ FAB-MS m /e  637.6 (M-H)‘
Scheme 3.2.2.6 One-pot synthesis procedure: adding base after activation step.
Hypothesizing that such a mechanism maybe occuring with the P(III) amino 
acids, we followed Hirschmann’s protocol by performing activation with PhsPCU without 
base, then added base second (Scheme 3.3.2.6). jIP NMR indicated that the chemical 
shift activated species 47 (3lP at 184 ppm, Fig. 3.3.3 H) was different than that formed in 
presence of base (Fig. 3.3.2 A). Also, the addition of base to 47 changed it to a species
54
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48 with 3IP at 164ppm (Fig. 3.3.3 I). The chemical shift of the coupling product 49 (Fig.
3.3.3 J )  was different than that of the product 38, which is formed when base was added 
in the activation step (Scheme 3.3.2.2). Oxidation and sulfiirization of 49 led to 
phosphonate products 50 and 51 (Fig. 3.3.3 K) respectively. So this new strategy did 
provide phosphonopeptide products, but they lacked the phosphonate ester protecting 
group (e.g. allyl).
To discover if this side reaction was caused by excess Ph3PCl2, a titration 
experiment was performed. When 0.5-0.75 equivalents of PhjPCli were added to 
phosphinate dipeptide 5 2 ,31P NMR analysis showed chemical shift at 31 and 32 ppm, not 
in the typical range for a phosphonochloridite (180-190 ppm) as was observed in 
activations with slight excesses of Ph3PCl2 (e.g. 47, Scheme 3.2.2.6). Addition of 
hydoxyl ester to this gave a 3lP NMR peak (34 ppm) consistent with regeneration of the 
starting phosphinate ester 52. Sulfurization provided a P(V) compound 54 which also 
lacked addition of the hydroxyl acid ester (FAB MS). Only when at least l . l  equiv. 
activating reagent were added were 31P NMR signals (8 180-190 ppm) for presumed 
phosphonochloridite obtained. When insufficient Ph3PC12 is added we propose that a 
mixed phosphorus species 53 is formed (Scheme 3.3.2.7), which reacts with alcohol to 
regenerate the phosphinate 52. Sulfurization of this (in the presence of TEA) leads to the 
the thiophosphonic acid 54 (See Chapter 4.?? for further details on the sulfurization of 
phosphinates). According to this experiment, less than one equivalent of Ph3PCl2 did not 
lead to any loss of the phosphinate ester group.
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hydroxy acid ester
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H OR'
31P  34 
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^  sulfur
S
R -f\-O H
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54
Scheme 33.2.7  Fewer equivalents of Ph3PCl2 caused no coupling of hydroxy acid ester.
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Fig. 3.3.3 3IP NMR spectra: H, activated species 47, 8 =  182.0,184.1; I, reaction 
with base to form 48, 8 = 164.4, 166.1; J , coupling product 49, 8 = 173.0, 
173.6; K, sulfurization product, 51, 8 = 76.5, 77.1, 77.8, 78.1; 
triphenylphosphine oxide, 8 = 27.5, 27.7; Ph3P=0«HCl, 8 = 40.2.
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An experiment was designed to study the reaction mechanism of the loss of 
phosphinate ester. Z-protected aminophosphonite neopentyl ester 19 (neopentyl ester 
should be difficult to cleaved by either an SN1 or SN2 mechanism) was treated with 1.5 
equiv. PI13PCI2  in the absence o f the base for 30 minutes. This solution then was 
analyzed by GC-MS (Fig. 3.3.4) which showed that the ester group was lost as neopentyl 
chloride 59 during activation. We have observed a similar same side reaction in our 
synthesis of phosphonamide haptens . 6 7  2-Chloro-2-methylbutane 63 was not detected in 
the reaction solution. Also no neopentyl alcohol (tr = 3.1 min, data not shown) was 
detected by GC-MS.
Based on these results we believe activation of phosphinates (e.g., 19, 36, etc.) in 
the absence or presence of the base does form phosphonochloridites 56 (Scheme 3.3.2.8), 
but in the absence of base, most likely the HC1 generated in the reaction cleaves off the 
alkyl phosphonate ester bond to give phosphonodichloridite 64. There are three possible 
paths to generate phosphonodichloridite 64 after phosphorus is protonated. In Path A, 
chloride attack on the P-protonated species 57a promotes an SN2-like reaction to break 
the oxygen-carbon bond in which neopentyl chloride 59 is generated as a co-product. In 
Path B, following the Ssl-like  cleavage of oxygen-carbon bond to generate a unstable 
primary carbon cation, a 1 , 2  methyl migration reaction would yield a stable tertiary 
carbon cation 62, and 2-chloro-2-methylbutane 63 would be formed. In Path C, transfer 
of the proton to the ester oxygen to form 57b followed by attach of chloride on the 
phosphorus would produce phosphonodichloridite 64 directly plus neopently alcohol.
58
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Y  Y
—  7 -U N  PZ-H N  R.
19 A
Z-H  R^»«
b*H Ph3PCI2
55
Z-H N
X p
Z" HN P' o ^ _  + Ph3P 0  + HCI
AT56
Z-H N
d e te c t e d  in G C -M S
I I ci -neopental 
Z—  N R© alcohQl ,
HCI
56 Z-HN ($ - 
H
57a
Path C Z-H N
SA
Z -H N  P -C I
+
63 > Y
d idn 't d e t e c t e d  in G C -M S
.2 CH3 shift
62 61
Scheme 3.3.2.8 Proposed mechanism of phosphonodichloridite formation.
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Fig. 3.3.4 Mechanistic studies of Ph3 PCl2  activation o f phosphonous amino acids (I): 
(A) GC spectrum of 2-chIoro-2-methyI-butane in DCM; (B) MS spectrum 
of 2 -chloro-2 -methyl-butane and library search result.
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Fig. 3.3.5 Mechanistic studies of PI13PCI2  activation of phosphonous amino acids 
(II): (A) GC spectrum of neopentyl chloride in DCM; (B) MS spectrum of 
neopentyl chloride and library search result.
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The fact that no rearranged 2-chloro-2-methyl butane is observed seems to eliminate Path 
B. The absence of neopentyl alcohol seems to discount Path C, however, it is known that 
Pl^PCh can convert alcohols to chlorides. Thus, the mechanism is either Path A, an Sn2- 
like cleavage to form neopentyl chloride (59), or Path C whereby neopentyl alcohol is 
initially formed and then subsequently converted to neopentyl chloride (59) by excess 
Ph3PCl2.
Also, when the base (1.2 equiv.) and nucleophile were added after activation, 
double coupling o f the incoming alcohol nucleophile to the phosphorus center was 
observed as FAB-MS m /e 811.8 (M+H)+ for Z-Phe-VaIvF[P(0)(0Phe-0M e)0]Phe-0M e 
and 827.6 (M+H)+ for Z-Phe-ValxF[P(S)(OPheOMe)0]Phe-OMe.
In Professor Hirschmann’s report, 6 6  the base was considered to be a nucleophile. 
It attacked on phosphorus center to provide an intermediate, phosphonylammonium salt, 
which was highly reactive phosphonylating agent, affording higher yields of phosphonate 
ester and amide. However, instead of TEA, when the non-nucleophilic base 2,6-di-t- 
butyl-4-methyl-pyridine was used in our reaction, we found hydroxyl acid ester was able 
to couple to the phosphinate activated species. This seemed to indicated that formation 
of phosphonitylammonium salt is not necessary for the condensation and the base may 
not be a nucleophile in our strategy.
In order to investigate whether or not the base played role of forming reactive 
intermediate B or C  as was the case in P(V) chemistry reported by Hirschmann6 6  
(Scheme 3.3.2.5), we developed a method in which solid-supported DIEA resins were 
used in the place o f TEA (Scheme 3.3.2.9). DIEA-PS is a highly loaded tertiary amine 
base that is a resin-bound equivalent o f DIEA. DIEA-PS is useful in applications
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requiring a tertiary amine base, where the resin-bound ammonium salt products are 
readily separated by nitration. So if the base reaction is an nucleophilic attachment, 
detecting31P NMR peaks on the solid support would prove this.
F m o c - N  P - 0 B n
Fmoc—N \
Cl
Xor Fmoc-N P 
H Cl 
B
DIEA-Resin
or
D
Fmoc y / \  C 02Me
H S ' bH
31 P: 87,89; FAB m/e 552 .5  (M -H)'
Scheme 3.3.2.9 DIEA resins as potential nucleophile in activation of phosphonites.
Fmoc-aminophosphonous acid ester 15 was activated by Ph3 PCl2  and the solution 
was transferred to a container holding DIEA-PS (Scheme 3.3.2.9). The resin and solution 
were separated by filtration and both phases were analyzed by 3iP NMR. On the solid 
support, no 3IP NMR signals were detected (except for some residual Ph3 P = 0  precipitate 
from the activation reaction); in the solution phase, only 3lP NMR peaks consistent with 
A or B were found ( 8  =  192). Next hydroxyl acid methyl ester 28a and then Sg were
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added successively. 3lP NMR analysis of the solution indicated the presence of 
thiophosphonate dipeptide product (8=87-89), which was also confirmed by FAB-MS. 
Since the activated aminophosphonate A or D did not bond to the DIEA-resin to form B 
or C, we conclude that generation o f phosphonitylalkylammonium salts does not occur in 
our synthetic approach.
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Scheme 3.4 Side reactions in phosphonous ester activation with PI13PCI2 .
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3.4 Summary
Based on these observations we propose pathways (Scheme 3.4) which account for 
successful coupling (Path A), the lack of coupling when phosphonous acids are activated 
in the presence of base (Path B), and the side reaction which removes the phosphonite 
ester protection (Path C). Thus, activation in the presence of base provides 
phosphonochloridite 64, but there is delicate balance between Path A, which leads to 
coupling products, and Path B which produces oxaphosphazoles 70 that are unreactive 
towards alcohols. This balance is driven to the cyclic derivative 70 by excess base, but 
even when limiting base is present, often little or no coupling products are formed. Thus, 
the exact nature of the amine and ester protecting groups and the side chain group on the 
phosphinate amino acid are also likely affecting the balance between 64 and 70. A 
similar cyclization can take place with phosphonodichloridite 65 to generate chloro- 
oxophosphazole 6 6  (Path C), which can couple with alcohols (R’OH, in this case 
phenyllactate esters) to generate 67. Oxidation or sulfurization of 67 followed by ring 
opening (presumably in the aqueous work-up) leads to phosphonate monoesters 6 8  
lacking the original protection group (Path C). When there is less base present (-1 
equiv.) phosphonochloridite 65 doesn’t cylcize, but rather can couple to 2 equiv. of 
alcohol nucleophile (R’OH) to produce phosphonite, again lacking the original 
phosphonate ester protection group (Path D). Oxidation or sufurization provide the 
thiophosphonate or phosphonate “double” esters 69 (Observed by FAB-MS and H- and 
3 lP-NMR).
66
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3.4 Experimental Material 
Technical information
Anhydrous DCM, pyridine, methanol, benzyl alcohol and DMF were purchased 
from Aldrich. Dichlorotriphenylphosphorane was stored and proportioned in a strictly 
anhydrous environment (dry argon box). DMF and 20% piperidine solution in DMF 
were obtained from Perseptive Biosystems. Fmoc amino acids were purchased from 
Advanced Chemtech. PAC-PEG-PS (0.15 mmol/g) resins were obtained from Perseptive 
Biosystems. Ultraviolet-visible spectra were performed on an AVIV 14DS UV-VIS-IR 
spectrophotometer.
Determination of coupling yield on Fmoc amino acid resin:54 
The substitution level of Fmoc amino acid resins is determined by quantitative 
spectrophonometric monitoring following piperidine deblocking. Fmoc amino acyl 
resins (4 to 8  mg) are shaken or stirred in piperidine-DMF (3:7) (0.5 mL) for 30 minutes, 
following which MeOH (6.5 mL) is added, and the resin is allowed to settle. The 
resultant fulvene-piperdine adduct has UV absorption maxima at 267 nm ( e  = 17,500 M ' 1 
cm '1), 290 nm ( e  = 5800 M 'cm '1), and 301 nm ( e  = 7800M'lcm '1). For reference, a 
piperidine-DMF-MeOH solution (0.3:0.7:39) is prepared. Spectrophotometric analysis is 
typically carried out at 301 nm, with comparison to a free Fmoc amino acid o f known 
concentration treated under identical conditions. The substitution level (mmol/g) = (A301  
x 106  mol/mol x 0.007 L/7800 M 'cm " 1 x 1 cm x mg of resin).
L-Phenyllactic acid, methyl ester (28a):
L-3-Phenyllactic acid (1.65 g, 9.9 mmol) was dissolved in CH1CI2 (12 mL) with methanol 
(1.2 mL) and 98% sulfuric acid (0.03 mL). The mixture was heated to reflux for 18 h.
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Then the reaction mixture was washed with water, saturated N aH C 0 3  and saturated 
NaCl. The organic layer was dried under reduced pressure to yield product. Yield: 1.59 
(8 8 %); mp 47-49 °C. lH NMR (250 MHz, CDC13) 8  2.68 (d, 7=5, OH), 3.05 (m, 2H, 
CH 2Ph), 3.78 (s, 3H, CH3), 4.46 (m, 1H, CH), 7.24 (m, 5H, Ph); Analysis cal’d for 
C i0 H,2 NO3: C, 66.64; H, 6.72; found: C, 66.81; H, 6.77.
L-3-PhenyIlactic acid, allyl ester (28b):
L-3-Phenyllactic acid (1.66 g, 10 mmol) was dissolved in CH3CN (25 mL), allyl bromide 
(2.6 mL, 30 mmol) and DIEA (2.6 ml, 15 mmol) was added successively. The mixture 
was stirred for 12 h at room temperature, diluted with EtOAc (30 mL), washed with 
water and dried under reduced pressure. Yield: 2.02 g (98%). 'H  NMR (200 MHz, 
CDC13) 8  3.07 (m, 2H, CH 2 Ph), 4.46 (t, J=2, 1H, CH), 4.70 (d, 7=2, 2H, CH=CH2), 5.31, 
(m, 2H, CH 2CH=CH2), 5.89 (m, 1H, CH=CH2), 7.24 (m, 5H, Ph). 
l-[-(9-Fluorenylmethoxycarbonyl)hydroxy]-3-phenyllactic acid, methyl ester (29): 
L-3-Phenyllactic acid, methyl ester (1.48 g, 8.2 mmol) was dissolved in pyridine (50 mL) 
at 0 °C. Fmoc-CI (2.6 g, 9.9 mmol) was added and the mixture was stirred for 2 h. 
Solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc, 
then washed with 0.5 N HCI. The organic layer was dried to give l-[-(9- 
fluorenylmethoxycarbonyI)hydroxy]-3-phenylIactic acid, methyl ester which can be used 
directly in next step.
l-[-(9-Fluorenylmethoxycarbonyl)hydroxy]-3-phenyllactic acid (30):
It was prepared by adding 1 N HCI (20 mL) and dioxane (20 mL) to l-[-(9- 
fluorenylmethoxycarbonyl)hydroxy]-3-phenyllactic acid, methyl ester (8.2 mmol). The 
mixture was heated to reflux for 5 h, then washed with saturated N aH C 0 3 and hexanes.
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The aqueous layer was extracted with CHCI3 (3 x 30 mL). The organic layer was washed 
with 0.5 N HCI, then dried under reduced pressure to give pure l-[-(9- 
fluorenylmethoxycarbonyI)hydroxy]-3-phenyllactic acid. Yield: 1.75 g (55%); ‘H NMR 
(250 MHz, CDCI3 ) 8  3.29 (m, 2H, CH2 Ph), 4.24 (m, 3H, CHnuorcnyi+CH^orenyi), 5.23 (m, 
1 H, CH), 7.35 (m, 9H, Ph+4Hnu0renyi), 7.50 (m, 2Hnu0renyi), 7.76 (m, 2Hnu0 renyi); Analysis 
cal’d for C2 4H 2 0O5: C, 74.21; H, 5.19; found: C, 74.43; H, 5.16.
Loading Fmoc hydroxy acid to PAC-PEG-PS resin (23):S7
Fmoc-protected hydroxyl acid 25 (44.2 mg, 0.11 mmol) and l-methylimidazole (Melm, 7 
mg, 0.08 mmol) were dissolved in CH2 C12  (1.5 mL). Under N2, the solution was 
transferred with a syringe to a flask containing the l-(2-mesitylenesulfonyl)-3-nitro- 
1,2,4-triazole (MSNT, 31 mg, 0.11 mmol). The mixture was immediately added to PAC- 
PEG-PS resins (200 mg, 0.19 mmol/g). After coupling 2 h, reactants were washed out 
with DCM ( 3 x 3  mL), DMF ( 3 x 3  mL) and DCM again ( 3 x 3  mL). The resins were 
dried in high vacuum. Fmoc UV analysis was performed on 4-8 mg resins. If the 
coupling yield was low, a second loading was carried out under the same condition. 
Yield: 87%. The loaded resins were capped with 0.2 M acetic anhydride in 0.28 M DIEA 
in DMF for 45 min. After removal of the Fmoc group with 20% piperidine solution in 
DMF ( 2 x 2  mL) for 15 min, the resins were washed with DCM ( 3 x 3  mL), DMF ( 3 x 3  
mL), DCM ( 3 x 3  mL), and dried under high vacuum.
Attem pted SPPS o f carboxypeptidase inhibitor Z-Phe-Val'F[(POOBn)0]-Phe-OH:
At room temperature, a solution of Ph3PCl2  (0.34 g, 42 equivalents) in DCM was added 
dropwise to a solution o f protected amino phosphorous acid ester 15 (0.13 g, 12 
equivalents) and TEA (0.02 mL, 20 equivalents) in DCM with stirring. 30 minutes later,
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the activated P(III) compound solution was added to the hydroxy-acid-loaded resin (200 
mg, 6 8 % loaded), followed by adding TEA (0.18 mL, 40 equivalents) under argon and 
left for 1 h. The resins were washed with anhydrous CH2CI2  ( 3 x 3  mL) and DMF ( 3 x 3  
mL), and treated with r-BuOOH (0.12 mL, 15 equivalents) for 1 h. Then resins were 
washed with DCM, DMF and DCM, dried in vacuum. The coupling yield (71%) was 
determined by Fmoc UV analysis. The protected phosphonopeptide-bound resins were 
treated with 20% piperidine in DMF to deprotect. Fmoc-protected phenylalanine ( 28 
mg, 3 equivalents) and HATU (27 mg, 3 equivalents) were dissolved in 0.28 M DIEA 
(0.45 mL, 5.3 equivalents) in DMF. Then the mixture was added to resin for 2h. Fmoc 
group was removed again and the resins were treated with solution of Z-OSu (67 mg. 5 
equivalents) in 0.3 M DIEA (, 15 equivalents) in DMF (2.8 mL) for 1.5 h. The putative 
phosphonopeptide analog was cleaved from the support by addition of a mixture of 8 8 % 
TFA, 5% phenol, 5% water, 2% triisopropylsilane for 2h. The resins were washed with 
CH 2 CI2 and the solvent removed. Water was added and the aqueous solution was washed 
with ether 3 times. The aqueous layer was evaporated in a centrifugal evaporator and 
analyzed by 3lP NMR and FABMS.
Attempted SPPS of carboxypeptldase inhibitor Z-Phe-Val'P[(PSOBn)0]-Phe-OH:
Coupling of protected phosphonous amino acid ester was performed according procedure 
described above. Instead of /-BuOOH, Sg (15 eq) in DCM was used for sulfurization. 
Coupling yield was 92%.
l-Amino-2-methylpropanephosphonous acid, tetrabutylammonium salt (31):
l-Amino-2-methyIpropanephosphonous acid 6  (0.69 g, 5 mmol) was dissolved in 
M eO H /ltO  (16.5 mL, 1:1). The solution was treated with (n-Bu)4 NOH (3.1 mL, 4.75
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mmol) and the mixture was stirring for 2h at room temperature. The solvent was 
evaporated under reduced pressure to give clear oily product. Yield: 1.95 g (100%). lH 
NMR (250 MHz, CDC13) 8  0.97 (m, 18H, CH 3 (n-Bu)4), 1.42 (m, 8 H, CH 2 (n-Bu)4). 1.60 
(m, 8 H, CH 2(/i-Bu)4), 2.09 (m, 1H, CH(CH3)2), 2.26 (m, 1H, CH), 3.28 (t, 8 H, C H 2 (n- 
B u )4), 7.00 (d, 7=465, 1H, P-H), 3lP (101 MHz, CDC!3) 5 30.3.
1-Amino-ethanephosphonous acid, tetrabutyl ammonium salt (32):
According to the procedure o f 31, starting with l-amino-ethanephosphonous acid 9 (1.52 
g, 13.9 mmol) and (n-Bu)4NOH (8.58 g, 13.2 mmol) to yield l-amino- 
ethanephosphonous acid, tetrabutyl ammonium salt 5.84 g (100%). 'H  NMR (250 MHz, 
CDC13) 5 0.99 (m, 12H, CH 3 (/i-Bu)4), 1.19 (2d, 7=6.95, 3H, CH 3), 1.45 (m, 8 H, CH 2 (n- 
Bu)4). 1.63 (m, 8 H, CH 2 (/i-Bu)4), 2.59 (m, IH, CHCH3), 2.29 (m, 8 H, CH 2(n-Bu)4), 6.80 
(d, 7=467.5, IH, P-H), 3lP (101 MHz, CDC13) 8  30.1.
Z-Phe-VaPF(PHO)-OH (33):
Benzyloxycarbonyl-phenylalanine (2.1 g, 7 mmol) and triethylamine (0.96 mL, 7 mmol) 
were dissolved in dry toluene (5 ml). The solution was cooled to -5  °C (ice bath with 
NaCl) and treated with trimethylacetyl chloride (pivaloyl chloride, 0.86 ml, 7 mmol). 
The mixture was stirred at -5  °C for 2 h, and then at room temperature for 1.5 h. 
Phosphinate salt 3 (4.08 g, 10.5 mmol) in DMF (10 mL) was added to the solution and 
the mixture was stirred for 24 h. Solvent was removed and the residue was dissolved in 
EtOAc (20 mL) and 0.5 N HCI (20 mL). The organic layer was dried under reduced 
pressure to give white solid. Yield: 2.66 g (91%). ’H NMR (200 MHz, DMSO-rfe) 8  
0.95 (m, 6 H, 2CH3), 2.06 (m, IH, CH(CH3)2), 2.86 (m, 2H, CH 2 Ph), 3.77 (t, 7=6,IH, 
CHCO) 4.41 (t, 7=6, IH , CHPO), 4.95 (s, 2H, CH 2Ph), 6.73 (d, 7=528, IH, P-H), 7.27
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(m, 10H, 2Ph), 7.54 (d, 7=8, IH, NH), 8.38 (d, 7=10, IH, NH); 3lP (101 MHz, DMSO- 
d6) 8  27.19,27.41; FAB-MS (NBA) m/e 419.3 (M+H)+.
Z-AIa-Ala^(PHO)-OH (34):
According to the procedure o f 33, staring with Z-Ala-OH (1.79 g. 8  mmol) and 1-amino-
2-methylpropanephosphonous acid, tetrabutylammonium salt (3.92 g, 9.5 mmol) to yield 
Z-Ala-AlaxF[(P H 0)0]-0H  (2.3 g, 97 %). lH NMR (250 MHz, CDC13) 8  1.25-1.47 (m, 
6 H, 2CH3), 3.25 (m, IH, CHCH3), 3.78 (m, IH, CHCH3), 5.11 (s, 2H, CH 2 Ph), 6.78 (d, 
7=558, IH, P-H), 7.32 (m, 5H, Ph); 3IP (101 MHz, CDC13) 8  32.7, 33.2; FAB-MS (NBA) 
m/e 315.4(M+H)+.
Z-Phe-Ala'F(PHO)-OH (35):
According to the procedure o f 33, staring with Z-Phe-OH (1.50 g. 5 mmol) and l-amino-
2-methylpropanephosphonous acid, tetrabutylammonium salt (2.15 g, 5 mL) to yield Z- 
Phe-Ala4/[(PHO)0]-OH (1.29 g, 6 6  %). lH NMR (250 MHz, CD3OD) 8  1.24(m, 3H, 
CH 3), 2.99(m. 2H, CHCH 2 Ph), 4.04 (m, IH, CHBn), 4.39 (m, IH, CHCH3), 5.06 (s, 2H, 
CH 2Ph), 6.77 (d, 7=557, IH, P-H), 7.23 (m, 10H, Ph); 31P (101 MHz, CD3OD) 8  30.6; 
FAB-MS (NBA) m/e 389.7 ((M-H) ).
Z-Phe-VaPF(PHO)-OAUyl (36):
Z-Phe-VaI*F(PHO)-OH 31 (0.42g, 1 mmol) and allyl ester (0.075 mL, 1.1 mmol) were 
dissolved in CH2 Cl2  ( 8  mL). DMAP (12 mg, 0.1 mmol) was added to the solution, then 
DCC (0.22 g, 1.1 mmol) was added. The mixture was stirred for 5 h, and diluted with 
EtOAc (60 mL), filtered and washed successively with 5% KHS04  (30 mL), saturated 
N aH C 0 3 (30 mL) and NaCl solutions (30 mL), dried over Na2S 0 4  and evaporated the 
solvent to give phosphonous monoester. Yield: 0.39 g (82%). 'H  NMR (200 MHz,
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CD3OD) 8  0.78-1.11 (2d, 6 H, 2CH3), 2.12 (m, IH, CH(CH3)2), 3.08 (m, 2H, CH 2 Ph), 
4.17 (m, IH, CHPO), 4.48 (m, 3H, CH=CH2+ CHBn), 5.07 (s, 2 H, CH2(Z)), 5.35 (m, 2H, 
NH + CH 2CH=CH2), 5.86 (m, IH, CH=CH2) 7.00 ( d, IH, P-H, 7=551), 7.26 (m, 10H, 
2Ph); 3lP (101 MHz, CD 3OD) 5 32.3,32.6,32.9; FAB-MS (NBA) m/e 495.3 (M +H )\ 
General experimental conditions for solution phase synthesis of phosphonopeptides 
At room temperature, a solution of Ph3 PCl2 (95% purity, Aldrich, 1.2 eq.) in CH2C12 was 
added dropwise to a solution of dipeptide phosphonous acid ester with stirring. 
Concentrations were chosen such that the reaction mixture contained 0.1 M dipeptide 
phosphonous acid ester. 30 min. later, TEA (3 eq.) was injected into the reaction solution 
to scavenge HCI. Then the solution was treated with hydroxyl acid ester (2 eq.) for 1.5 h, 
followed by addition of t-BuOOH or Sg (10 eq.) for at least 1.5 h. The solution was 
washed with saturated aqueous N aHC0 3 and dried over Na2S 0 4. 3IP and FAB-MS 
identified the compounds.
Synthesis of Z-Phe-VaPF[(P02Allyl)0]-Phe-OAllyl (39):
At room temperature, a solution of Ph3 PCl2  (95% purity, Aldrich, 1.5 eq.) and TEA (3 
eq.) in CH 2 C12 was added dropwise to a solution of Z-protected dipeptide phosphonite 
ZFVp-0A llyl (0.19g, 0.4 mmol) with stirring for 45 min. Then the solution was treated 
with hydroxyl acid allyl ester (0.12g, 0.6 mmol) for 1.5 h (3lP NMR 136), followed by 
addition o f t-BuOOH (0.12 mL, 4 mmol) for at least 1.5 h. The solution was washed 
with saturated aqueous NaHC03 and dried over Na2 S 0 4  to give 0.487g. After flash 
Column chromatograph (CHCl3-EtOAc 5:1), desired product was obtained (O.lOlg, 
38%). 3lP (101 MHz, CDC13) 8  23.8,24.2; FAB-MS m/e 663.2 (M+H)+.
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Preparation and test of resin-bound PhsPCh (4D :64
The resin-bound PhjP (0.5 g, 1.5 mmol) was swelled in DCM (2 mL), and a solution of 
triphosgene (0.148 g, 0.5 mmol) in DCM (I mL) was added whilst cooling to maintain 
the temperature at 20 °C. After the addition the reaction was stirred until gas evolution. 
Solid-phase 31P NMR showed a broad Ph3PCl2  signal 58.3 ppm. A solution of Fmoc 
amino phosphonite (0.154 g, 0.3 mmol) and triethylamine (0.068 mL, 0.5 mmol) in 
dichloromethane was injected into the flask containing resin-bound Ph3 PCl2. The 3IP 
NMR signal of the activating species was detected 5 192 ppm, as well as other by­
products 8  218, 233, 234 ppm. However, after coupling with hydroxyl acid ester and 
followed by oxidation step, the product was detected (25 ppm) with other by-product 34 
ppm.
Preparation and test of PhjPFj (42):65
Triphenylphosphine (43 mg, 0.16 mmol), potassium hydrogen fluoride (65 mg, 0.83 
mmol), and dry DMF (2 mL) were placed in an NMR tube under argon. The solution 
was shaken to dissolve the triphenylphosphine, cooled to 0 °C, and following the addition 
of diisopropylazodicarboxylate (33 pL, 0.16 mmol), placed in a sonic bath for 2 hrs. 3IP 
NMR showed clean conversion to diflorotriphenylphosphorane 8  55.8 ppm. Also present 
was a small singlet at 8  25.1, due to triphenylphosphine oxide. A solution of Fmoc 
amino phosphonite (30 mg, 0.06 mmol) and triethylamine (0.02 mL, 0.1 mmol) in 
dichloromethane (1 mL) was injected into the NMR tube. But no the 3lP NMR signal of 
the activating species was detected.
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Synthesis of Z-Phe-Val'F[(P02')0]-Phe-OAUyl (50) by general procedure:
At room temperature, a solution of Ph3 PCl2  (1.1 eq.) in CH2 CI2  was added to a solution of 
Z-protected dipeptide phosphonite 36 (172 mg, 0.38 mmol). After 30 minutes, 3IP NMR 
indicated peaks o f activated P(III) compound (5=182, 184). This solution was treated 
with TEA (0.15 mL, 1 mmol) for 60 minutes (8=179, 180), followed by adding L- 
phenyllactic acid allyl ester 28b (116 mg, 0.56 mmol). 3lP NMRs showed peaks (8173, 
174). r-Butylperoxide (0.5 mL, 3.8 mmol) was used for oxidation step for 2 h. 31P (101 
MHz, CDCI3) 8  25.4, 25.7; FAB-MS m/e 621.2 (M-H)\
Synthesis of Z-Phe-VaPF[(POS')0]-Phe-OAIlyl (51) by general procedure:
At room temperature, a solution of Ph3PCl2 (1.1 eq.) in CH2CI2 was added to a solution of 
Z-protected dipeptide phosphonite 36 (260 mg, 0.57 mmol). After 30 minutes, 3,P NMR 
indicated peaks of activated P(IH) compound (8=182, 184). This solution was treated 
with TAE (0.3 mL, 1.6 mmol) for 60 minutes (5=179, 180), followed by adding L- 
phenyllactic acid allyl ester (175 mg, 0.85 mmol). 3IP NMRs showed peaks (8 = 173,
174). Sulfurization was completed through treated with sulfur (0.18 g, 5.7 mmol) for 4 h. 
3IP NMR indicated the peaks of product clearly (8=76-78,94,95); FAB-MS m/e 637.2 
(M -H)\
Reaction mechanism studies:
A Z-protected aminophosphonous acid neopentyl ester 19 was treated with 1.5 eq. 
Ph3PCl2  in the absence o f base for 30 minutes. The solution then was filtered through 
DIEA resins to remove HCI. The nitrate was then injected to GC-MS to analyses. GC- 
MS: m /z 55 ,57,91 (M +l, 78%).
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Non-nucleophilic base experiment:
2,6-d/-f-Butyl-4-methyl-pyridine was used instead of TEA or DIEA, it was found that 
hydroxyl acid ester was able to couple to the phosphinate acid ester (Scheme 3.2.2.8). 3lP 
(101 MHz, CDCI3 ) 8  76.4,78.0; FAB-MS m/e 637.6 (M-H)\
DIEA-PS base experiment:
In an argon glovebox, Fmoc-aminophosphonous acid benzyl ester (90 mg, 0.2 mmol) was 
activated by 1.5 equivalents of PhsPCb. The solution was transferred to a container 
holding DIEA-PS (272 mg, 5 equiv.). After 2 h, the resins were filtered off. Both 
solution and resin were taken out to run 3lP NMR. In solid phase, no desired peak was 
detected; in solution phase, only activation peaks were found: 31P (101 MHz, CDCI3 ) 8  
192.
In next experiment, followed by base attachment step, hydroxyl acid methyl ester was 
injected in for 2 h, then Sg. 3,P NMR studies indicated that after injection of activated 
aminophosphonous acid ester to resin-bound DIEA-PS, the mixture o f the resins and 
solution displayed the peak of activation (8=192) and the peak of Ph3PO (8=27.5); the 
resins themselves just had Ph3PO signal. When sulfurization step finished, the dipeptide 
product peaks were found in solution; 31P (101 MHz, CDC13) 8  87, 89; FAB-MS m/e
552.5 (M-H)\
Z-Phe-Val'P(PHO)-OBn (52):
Z-Phe-ValvP(PHO)-OH 31 (0.26g, 0.6 mmol) and benzylester (0.071 mL, 0.66 mmol) 
were dissolved in CH^CL (5 mL). DMAP ( 8  mg, 0.06 mmol) was added to the solution, 
then DCC (0.16 g, 0.66 mmol) was added. The mixture was stirred for 5 h, and diluted 
with EtOAc (30 mL), filtered and washed successively with 5% KHSO4  (20 mL),
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saturated NaHCC>3 (20 mL) and NaCI solutions (20 mL), dried over Na2SC>4 and 
evaporated the solvent to give phosphonous monoester. Yield: 0.29 g (90%). ’H NMR 
(250 MHz, CD3OD) 5 0.76-1.11 (2d, 6 H, 2CH3), 2.15 (m, IH, CH(CH3)2), 3.06 (m, 2H, 
CH 2 Ph), 4.15 (m, IH, CHPO), 4.45 (m, IH, CHBn), 5.07 (m, 4H, C H 2(Bn) + CH2(Z)), 5.25 
(d, IH, NH), 7.00 ( d, IH, P-H, J=551), 7.26 (m, 15H, 3Ph); 31P (101 MHz, CD 3 OD) 8  
33.8,34.0, 34.3.
PI13PCI2  titration
At room temperature, a solution of Ph3 PCl2  (0.2-0.3 mL, 0.5-0.75 equiv.) in CH2C12  was 
added dropwise to a solution of dipeptide phosphonous acid ester 52 (76 mg, 0.15 mmol) 
with stirring. Concentrations were chosen such that the reaction mixture contained 0.1 M 
dipeptide phosphonous acid ester. 3lP NMR (38 ppm) showed no activation signal. 
DIEA (0.078 mL, 3 eq.) was added into the reaction solution to scavenge HCI. Then the 
solution was treated with hydroxy acid ester 28b (93 mg, 3 equiv.) for 1.5 h, followed by 
addition of Sg (32 mg, 10 equiv.) for at least 1.5 h. The solution was washed with 
saturated aqueous NaHC0 3 and dried over Na2 S0 4 . 31P (101 MHz, CD3OD) 8  73, 74; 
FAB-MS m/e 539.2 (M-H)\
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CHAPTER 4. SYNTHESES OF PHOSPHONATE AND 
THIOPHOSPHONATE PEPTIDE ANALOGS BY 
ESTERIFICATION-OXIDATION STRATEGY
Although the P(HI) chemistry we developed to synthesize phosphono- and 
thiophosphonopeptide (Chapter 3) has the advantage such as less reaction time needed, 
we experienced many side reactions. In this chapter, an alternative strategy for preparing 
phosphonate and thiophosphonate peptide analogs is illustrated. After the phosphonous 
acid dipeptide analogs are made, esterification is completed in the presence o f 
DCC/DMAP or just EDC. The reduced phosphorus [P(III)] tripeptide derivatives are
50,70 51,71
72, 73 74, 75
Ph Ph
76, 77 78, 79
50, 51, 72, 74, 76,78: R = Allyl; 70, 71,73, 75, 77, 79: R = CH3
Fig. 4 Phosphonate and thiophosphonate peptide analogs.
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oxidized by sodium periodate to afford the P(V) peptide analogs; or sulfurized by Ss in 
pyridine/carbondisulfide solution to give thiophosphonopeptide products (Fig. 4.1). This 
approach avoids some o f the side reactions we experienced when using one pot strategy 
and the reaction condition is relative milder. The methyl ester protecting groups are 
cleaved by lithium n-mecaptide in hexamethylphosphoramide; and the allyl ester 
protecting groups are deblocked by reactions catalyzed with Pd(PPh3 ) 4  Sep-Pak or HPLC 
column purification gives the target molecules.
4.1 Synthesis of Phosphonotripeptide Analogs
Karanewsky and Badia (1986) described a strategy5 1  to make phosphonites by 
condensing amino phosphonous acids with alcohol. Following this procedure, we 
coupled the Z-protected phosphonous acid dipeptide analogs directly to C-terminal a -  
hydroxy acid ester by carbodiimide mediated dehydration to give H-phosphonite 
tripeptide analogs 80-85 in 80-90% yields (Scheme 4.1.1).
2.DMAP
3.DCC
1 .Hydroxyl acid es te r
80: R 1=Bn, R2=/Pr, R=Me; 81: R ^ B n , R2=/Pr, R=Allyl; 
82: R1=Bn, R2=Me, R=Me; 83: R ^ B n , R2=Me, R=Allyl; 
84: R 1=Me, R2=Me, R=Me; 85: R 1=Me, R2=Me, X=Allyl.
Scheme 4.1.1 Synthesis o f H-phosphonites tripeptide analogs.
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However, using the purification procedure51 described by Karanewsky and Badia, 
we were not able to get pure products since aqueous extraction couldn’t remove all DCU 
by-products. Applying a modification of the carbodiimide-mediated approach, the 
phosphonous acids and hydroxy acid esters were coupled with l-[3- 
(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (Fig. 4.2) in a yield of 
70-90%. We found that the catalyst DMAP was unnecessary when using EDC as the 
activator and the EDC was more easily removed from the products by simple aqueous 
extraction. Use o f the water-soluble carbodiimide proved to be important in facilitating 
the reaction workup, since silica gel chromatography, to which the phosphinate esters 
were not stable, could be avoided.
H3C,
N -C H 2CH2CH2-N = C = N -C H 2CH3 .HCI
h 3c
Fig. 4.1 l-[3-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC).
Following the literature procedure, 51 oxidation o f H-phosphintes 80-85 with 
sodium periodate produced the phosphonate peptide analogs 50, 70, 72, 73, 76 and 77 
(Scheme 4.1.2).
Iioxane
80-85 50, 70, 72, 73, 76, 77
Scheme 4.1.2 Oxidation of H-phosphinates.
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In oligonucleotide chemistry, the synthesis of an oligodeoxynucleotide containing 
phosphorothioate diester can be accomplished by sufurization of phosphite intermediates 
with elemental sulfur in carbon disulfide/pyridine.6 8  However, when H-phosphonates 
intermediates are used, sulfur requires the presence of more basic tertiary amine like 
TEA . 6 9  In analog to this, direct sulfurization of H-phosphinates by S8 in 
pyridine/carbondisulfide required the presence of TEA to provide thiophosphonates 51, 
71, 74, 75, 78, 79 in 40-80% yields (Scheme 4.1.3). Purification by flash 
chromatography resulted in loss of products. It might be caused by hydrolysis of 
products on silica gel or low solubility of the charged products in the organic mobile 
phase . 16 The desired compounds were confirmed by FAB-MS, *H and 3IP NMR. The 
compounds were hard to be isolated from DCC and the reaction by-product DCU, the 
purity were 39%-44%of according to HPLC analysis.
5 2  H H £  ► =2 H 1 £
OH =
80-85 5 1 ,7 1 ,7 4 ,7 5 ,7 8 ,7 9
Scheme 4.1.3 Sulfurization of H-phosphinates.
4.2 Esters Deprotection
4.2.1 Deprotection of Methyl Esters
Lithium n-propyl mercaptide in hexamethylphosphoramide (HMPA) is an especially 
effective reagent for the cleavage of methyl ester under mild conditions. The reaction 
proceeds readily at room temperature by an Sn2 mechanism. 7 0  The reagent was prepared
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by adding freshly n-propyl mercaptan to a suspension o f ground lithium hydride in pre­
purged HMPA under argon, stirred for 1 h, then followed by filtration without contact 
with air. The reagent was stored at 0 °C without removal o f the excess mercaptan . 71
The tripeptide analogs Z-Phe-Val\j/[P(0 2 ')0 ]Phe-0 Me 70 and Z-Phe- 
Val\j/[P(0S)0]Phe-0H 71 were treated with n-propyl mercaptide (0.46 M) in HMPA for
2.5 h. The mixture was diluted with water, and washed six times with CHCI3 to remove 
HMPA. The aqueous phase was lyophilized to yield a white powder. The tripeptide 
analog sample was dissolved in 50 mM TEAA, loaded to a Cis Sep-Pak cartridge, which 
was prewashed with Water, MeOH, and 50 mM TEAA. The sample was eluted with 0% 
to 80% CH3 CN in 50 mM TEAA. The desired tripeptide analogs l a  and lb  were 
obtained in the form of triethylammonium salts after Sep-Pak Column purification. 
However, employing this deprotection strategy to other methyl esters 73, 75, 77 and 79, 
either led to no cleavage or decomposition of the starting materials, which indicated these 
phosphonopeptides were not stable as 70 and 71 to the cleavage reagent.
> -N H  O y y -N H 0 y
°  n  ? n 1,CH3CH2CH2S U / 0  V - f  r *  Bn
Bn HN— (  1 HMPA Bn' HN— (  T ^
0 * P \ - °  c o 2c h 3 --------------------------------   J p x- °  c o r
X—. 2. S ep -P ak  column 0  x
u  purification Q
70: X = O; 71: X = S  ia :X = 0 ;  1b:X  = S
Scheme 4.2.1 Deprotection of methyl esters.
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4.2.2 Deallylation of Allyl Esters
Allyl and allyloxyxarbonyl groups are used for the protection of amino acids72,73 and as 
linker for solid-phase peptide synthesis.74,73 The use of such anchoring groups for the 
synthesis of protected peptide segments is attractive because, in principle, they are 
compatible with both the Boc- and Fmoc- peptide synthesis strategies. Moreover for the 
Fmoc strategy the allylic anchor provides a three-demensional orthogonal protecting 
scheme. The protecting groups may be selectively cleaved using various nucleophile 
reagents under palladium catalysis.76,77 The mechanism of “allyl” group deprotection 
involves the formation of an allyl-palladium complex which further reacts which the 
nucleophile to give X ' and the regenerated catalyst (Scheme 4.2.1).72 We felt that under 
these mild conditions, that final ally ester cleavage would occur and the 
phosphonopeptides would be stable.
Nu0  _  ^  ©
Pd° catalyst
Scheme 4.2.2.1 The mechanism of allyl group deprotection.
The catalyst tetrakis(triphenylphosphine) palladium (0) was prepared.78 The 
mixture o f palladium dichloride and triphenylphosphine in dimethyl sulfoxide (DMSO) 
was heated to 140 °C. Hydrazine hydrate was then rapidly added. After crystallization, 
yellow crystalline product was obtained (91% yield).
1 . P d C I 2/ D M S O  
Heat
2. NH2NH2H20
P P h 3 ------------------------------   Pd(PPh3)4
Scheme 4.2.2.2 Preparation o f tetrakis(triphenylphosphine) palladium (0).
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Phosphonopeptide allyl ester was dissolved in dichloromethane or DMF. To the 
flask was then added 2 equivalents morpholine or PhSiHj, followed'by Pd(PPh3 )4 . The 
solution was stirred at room temperature for 60 minutes. Polystyrene supported PPh3 
resins were added to scavenge Pd and stirred for 60 min, then filtered off by suction 
filtration and washed with DCM. All solvents were evaporated by reduced pressure, and 
the products were dried under vacuum. Purification was performed with Sep-Pak or 
reverse phase HPLC to get oily products.
0. 1. morpholine Q
^ ~ N H  O or PhSiH3 ^ - N H  O
0  > H :  Ra Bn 2. Pd(PPh3)4 O > - (  R2 Bn
Ri HN—(  X 3. P P h3-Resin HN—< X <=>
n ^ P -0  C02Allyl------------ ► n * P r°  CG^
°  x 4. Sep-Pak °  \
© purification . . . .  . . . ©
5 0 ,5 1 ,7 2 ,7 6 ,7 8  1a, 1b,1 c, 1e,1 f
Scheme 4.2.2.3 Deprotection of allyl esters.
74
Fig. 4.2.1 HPLC of Profile Z-Phe-Ala'P[(POS )0]-Phe-OAllyl 74. linear gradient over 60 
min of 65% solution A (0.25M ammonium acetate in HiO) and 35% solution B 
(0.05M ammonium acetate in CH3CN-H2O 4:1); purity 39%; tR= 15.9 min.
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50
(1)
1a
(2)
Fig. 4.2.2 HPLC of profiles of 50 and la . (1) Z-Phe-Val4 /[(P0 2 ’)0 ]-Phe-0 AIlyl 50;
linear gradient over 60 min o f 65% solution A (0.25M ammonium acetate in 
H2 0 )  and 35% solution B (0.05M ammonium acetate in CH 3CN-H 2O 4:1); 
purity 44%; tR= 15.1,15.9 min. (2) Z-Phe-Val4 /[(P0 2 ")0 ]-Phe-0 H la ; 
linear gradient over 60 min o f 65% solution A (0.25M ammonium acetate in 
H2 0 )  and 35% solution B (0.05M ammonium acetate in CH 3CN-H 2O 4:1); 
purity 76%; tR= 10,10.5 min
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51
-Sit*!
(1)
1b
(2)
Fig. 4.2.3 HPLC of profiles o f 51 and lb . (1) Z-Phe-VallF[(P0S‘)0]-Phe-0Allyl 51;
linear gradient over 60 min o f 65% solution A (0.25M ammonium acetate in 
H2O) and 35% solution B (0.05M  ammonium acetate in CH3CN-H20  4:1); 
purity 42%; tR= 28.8min. (2) Z-Phe-Val'P[(P0S')0]-Phe-0H lb;linear 
gradient over 60 min o f 65% solution A (0.25M ammonium acetate inH20 )  and 
35% solution B (0.05M ammonium acetate in CH3CN-H20  4:1); purity 8 8 %; 
tR = 9 .7 ,10.5 min
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Fig. 4.2.4 HPLC of profiles o f 76 and le . (1) Z-Ala-AlavP[(P0 2 )0]-Phe-0Allyl 
76; linear gradient over 60 min of 65% solution A (0.25M ammonium 
acetate inH20 )  and 35% solution B (0.05M ammonium acetate in 
CH3 CN-H20  4:1); purity 43%; tR= 17.2 min. (2) Z-Ala-AlaTKPO^O]- 
Phe-OH le ; linear gradient over 60 min of 95% solution A (0.1M TEAA 
in H20 )  and 5% solution B (0.02M TEAA in CH3CN-H2 0  4:1), flow rate 
1 mL/min on a C-18 column; purity 6 %;tR= 24.6 min.
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(1)
4<H
» -
(2)
Fig. 4.2.5 HPLC of profiles of 78 and If. (1) Z-Ala-Ala'F[(P0S )0]-Phe-0AIlyl 78;
linear gradient over 60 min of 65% solution A (0.25M ammonium acetate in 
H2O) and 35% solution B (0.05M ammonium acetate in CH3 CN-H20  4:1), 
purity 65%; tR= 15.8 min. (2) Z-Ala-Ala4'[(P0S*)0]-Phe-0H If; linear 
gradient over 60 min of 95% solution A (0.1M TEAA in H20 )  and 5% 
solution B (0.02M TEAA in CH3CN-H20  4:1), flow rate 1 mL/min on a C- 
18 column; purity 10%;tR = 24.1 min.
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Fig. 4.2.6 HPLC of profiles of 72 and lc . (1) Z-Phe-AlavP [(P 0 2 )0]-Phe-0A llyl 72; 
linear gradient over 60 min of 95% solution A (0.1M TEAA in H2 0 )  and 
5% solution B (0.02M TEAA in CH 3 CN-H 2 0  4:1), flow rate 1 mL/min on a 
C-18 column; purity 38%;tR= 23.5, 24.6 min. (2) Z-Phe-Ala'P[(P02 ')0 ]- 
Phe-OH lc . linear gradient over 60 min o f 95% solution A (0.1M TEAA in 
H2 0 )  and 5% solution B (0.02M TEAA in CH 3CN-H 2 0  4:1), flow rate 1 
mL/min on a C-18 column; purity 62%;tR =  28.7 min.
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We could not obtain some target molecules. In some cases, after deprotection o f allyl 
ester, only the starting reagents, peptide esters, were found. It’s probably because the 
anion moiety, bonded with phosphorus atom, attacks the palladium complex to deactivate 
the catalyst. In some cases, phosphonopeptides were obtained after deblocking the 
thiophosphonopeptide esters. We assumed that S ' reacted with palladium catalyst to form 
a thioallyl ester, which during the aqueous workup process was hydrolyzed to displace 
the sulfur moiety. (Scheme 4.2.2.4)
Scheme 4.2.2.4 Possible mechanism of Desulfurization of thiophosphonopeptide to
4.3 Enzyme Assays
The effectiveness o f a molecule as a reversible enzyme inhibitor is gauged quantitatively, 
usually by the inhibition constant K\ but also by the rate constant for dissociate,
The approaches to determination of very low inhibition constants rely on the 
independent determination of the association and the dissociation constants, koa and k0ff, 
respectively. If inhibition is reversible, the ratio of kQff/kon can be taken as K\. While £0ff 
is most readily determined by measuring the rate o f inactivation of the enzyme as a 
function o f inhibitor concentration, methods for determining kM vary. Determinations of
phosphonopeptide.
E  + 1 E * l KS =  W A b n  =  [ E ] [ l ] / [ E * l ]
*off
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K\ s of CPA inhibitors la  and lb  required the used of a coupled assay to determine itoff 
because of the extremely slow dissociation of the inhibitors from CPA (Scheme 4.3) . 2 2
CPA*Inhibitor - — — -  CPAfree + Inhibitor
free CPA
HO"
° e
NADLactate
dehydrogense
NADH, H
Tyrosine
am inotransferase
.0
Glu0@  aKg
Scheme 4.3 Kinetic enzyme assay to measure dissociate of inhibitors from
carboxypeptidase (CPA): rate of NADH production is measured by 
fluorescence (Aex = 340 nm; Aem = 450 nra) and is proportional to 
[CPAfree]*
Our results with the known ZFVp(0)F  inhibitor la  agree with the Bartlett’s 
value: 18 = 105 M^s ' 1 (literature 2.1 x 105  M ' s 1); k0a = 4.5 x 10' 9 M 's ’ 1 (literature
2.9 x 10' 9  M'*s'1); and the inhibition constant K\ -  1.1 x 10' 14 M (literature 1.4 x 10' 14 M). 
We have also analyzed the thiophosphonate inhibitor lb  and shown for the first time that 
thiophosphonates are also extremely potent inhibitors of the zinc protease CPA: 
ko„ = 3 x 1 0 5  M V ;  i to f f  = 3.9 x 1 0 ' 9  M V 1; and Kt = 1.3 x 1 0 *,5 M .
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4.4 Experim ental M aterial
Analytical HPLC were performed on SUPELCOSIL LC 18S (0.46 x 25 cm), module on 
PERKIN ELMER 200 series autosampler and pump equipped with 785A UV/VIS 
detector. The preparative HPLC were performed on Waters PrepLC 25mm (2.5 x 10 
cm), module on a Waters Millipore 600 E system equipped with a variable wavelength 
detector and an autoinjector.
Z-Phe-VaI*F[(PHO)0]-Phe-OMe (80):
Z-Phe-Val4/[(PHO)]-OH (0.63 g, 1.5 mmol) 34 and L-3-phenyllactic acid, methyl ester 
(0.3 g, 1.65 mmol) were dissolved in CH2CI2 (10 mL). DMAP (18 mg, 0.15 mmol) was 
added to the solution, then DCC (0.32 g, 1.58 mmol) was added. The mixture was stirred 
for 5 h, and diluted with EtOAc (100 mL), filtered and washed successively with 5% 
KHSO4  (60 mL), saturated NaHC0 3  (60 mL), and NaCl solutions (60 mL), dried over 
Na2S0 4  and evaporated the solvent to give phosphonous monoester. Yield: 0.85 g (97%). 
*H NMR (250 MHz, CDC13) 8  0.72-0.95 (2d, 6 H, 2CH3), 1.95 (m, 1 H, CH(CH 3 )2 ), 3.14 
(m, 4H, 2CH2 Ph), 3.78 (m. 4H, OCHCO+CH3), 4.11 (m, 1H, CHCO), 4.48 (m, 1H, 
CHPO), 5.06 (m, 2H, CH2(Z)), 6.29 (d, 7=7, 1 H, NH), 6 . 6 6  (d, 7=565, 1 H, P-H), 7.26 (m, 
15H, 3Ph); 3,P (101 MHz, CDC13) 5 31.8, 32.9, 34.6; FAB-MS m/e 581.0 (M+H)+. 
Z-Phe-VaPF[(PH0)01-Phe-0Allyl (81):
Z-Phe-Val'P[(PHO)]-OH 34 (0.84g, 2 mmol) and L-3-Phenyllactic acid allyl ester (0.46 
g, 2.2 mmol) were dissolved in CH2CI2 (15 mL). DMAP (24 mg, 0.2 mmol) was added 
to the solution, then DCC (0.43 g, 2.1 mmol) was added. The mixture was stirred for 5 h, 
and diluted with EtOAc (120 mL), filtered and washed successively with 5% KHSO4  (60 
mL), saturated N aH C0 3 (60 mL) and NaCl solutions (60 mL), dried over Na2 S 0 4  and
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
evaporated the solvent to give phosphonous monoester. Yield: 1.08 g (8 6 %). *H NMR 
(250 MHz, CD 3 OD) 8  0.78-1.11 (2d, 6 H, 2CH3), 2.12 (m, 1H, CH(CH3)2), 2.26 (m, IH, 
CHCO) 3.08 (m, 4H, 2CH 2 Ph), 4.05 (m, 1H, CHPO), 4.50 (m, 3H, CH=CH2+ OCHCO),
5.18 (m, 2H, C H 2(Z)), 5.30 (m, 2H, C H 2CH=CH2), 5.81 (m, IH, CH=CH2) 7.25 (m, 15H, 
3Ph); 3IP (101 MHz, CD 3OD) 8  32.3, 32.6, 32.9.
Z-Ala*Ala'F[(PHO)0]-Phe-OM e (84).
A 25-mL round bottom flask was charged with a solution of Z-Ala-AlaH'tfPHOjOJ-OH 
36 (157 mg, 0.5 mmol) and hydroxyl acid methyl ester (99 mg, 0.55 mmol) in 5 mL 
CH2C12. EDC (lOOmg, 1.05 mmol) was added. The mixture was stirred at room 
temperature for 20 h. The solution was diluted with EtOAc (60 mL), washed with 
saturated KH2P0 4  (60 mL), saturated N aH C 0 3 (60 mL) and brine (60 mL), dried over 
Na2S0 4 , and evaporated to give peptide(PIH) analog. Yield: 182 mg, (77% yield). lH 
NMR (250 MHz, CDC13) 8  1.12-1.52(m, 6 H, 2CH3), 3.69 (m, 3H, CHCO+CH 2 Ph), 3.72 
(d, IH, OCHCO), 3.78 (s, 3H, OCH3), 4.46 (m, IH, CHPO), 5.10 (m, 2H, CH2(Z)), 7.20 
(d, 7=587, IH, P-H), 7.28 (m, 10H, 2Ph); 31P (101 MHz, CDC13) 5 33.0, 33.8, 35.6, 36.0; 
FAB-MS m/e A l l .5 (M+H)+.
Z-Ala-Ala'F[(PHO)0]*Phe-OAIlyl (8 6 ):
According to procedure of 84, staring with Z-Ala-AIa'F[(PHO)]-OH 36 (0.4 g, 1.3 mmol) 
and L-3-Phenyllactic acid allyl ester (0.29 g, 1.4 mmol) to yield Z-Ala-Ala4/[(PHO)0]- 
Phe-0Allyl (583 mg, 91%). *H NMR (250 MHz, CD 3 OD) 8  0.94-1.30 (m, 6 H, 2CH3), 
3.10 (m, 4H, 2CH 2 Ph), 3.29 (m, IH, CHCO), 4.26 (m, IH, CHPO), 4.47 (t, IH, 
OCHCO), 4.65 (m, 2H, CH=CH2), 5.10 (m, 2H, C H 2(Z)), 5.36 (m, 2H, CH 2CH=CH2),
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5.95 (m, IH, CH=CH2), 6.98 (d, 7=560, IH, P-H), 7.25 (m, 10H, 2Ph); 3lP (101 MHz, 
CD 3OD) 8  32.7,34.6, 34.8; FAB-MS (NBA): m/e 503.5 (M+H)+. 
Z -Phe-A la4 '[(PH 0)0]-Phe-0M e (82):
According to procedure of 84, staring with Z-Phe-Ala'P[(PHO)]-OH 35 (0.59 g, 1.5 
mmol) and L-3-Phenyllactic acid methyl ester (0.30 g, 1.7 mmol) to yield Z-Phe- 
Ala'F[(PHO)0]-Phe-OMe 82 (0.73 g, 93%). ‘H NMR (250 MHz, CDC13) 5 1.03-1.31 
(m, 3H, CH3), 3.10 (m, 4H, 2CH2 Ph), 3.22 (t, IH, (OCH(Bz)CO), 3,72 (s, 3H, CH3),
4.19 (m, IH, CHCO), 4.37 (m, IH, CHPO), 5.08 (s, 2H, CH2(Z)), 6 . 8 8  (d, 7=565, IH, P- 
H), 7.26 (m, 10H, 2Ph); 3IP (101 MHz, CDC13) 5 32.6, 34.9, 35.2; FAB-MS m/e 553.7 
(M+H)+.
Z-Phe-A la'P[(PH 0)0]-Phe-0A llyl (83):
According to procedure of 84 with EDC instead of DCC/DMAP, staring with Z-Phe- 
AlaH/[(PHO)]-OH 35 (0.39 g, 0.8 mmol) and L-3-Phenyllactic acid allyl ester (0.18 g, 
0.88 mmol) to yield Z-Phe-AlavF[(PHO)0]-Phe-OAllyl 83 (393 mg, 85 %). ‘H NMR 
(200 MHz, CDCI3) 5 0.94-1.30 (m, 3H, CH3), 3.10 (m, 4H, 2CH2 Ph), 4.17 (m, IH. 
CHCO), 4.27 (m, IH, CHPO), 4.65 (m, 3H, OCHCO+CH=CH2), 5.07 (m, 2H, CH 2(z)), 
5.37 (m, 2H, CH 2CH=CH2), 5.88 (m, IH, CH=CH2), 6.98 (d, 7=560, IH, P-H), 7.25 (m, 
15H, 3Ph); 3,P (101 MHz, CD3OD) 5 33,35, 35.4,35.7; FAB-MS (NBA): ni/e (M +H f. 
Z-Phe-ValvP [(P 0 2 )0]-Phe-O M e (70):
Z-Phe-Val'P[(PHO)]-Phe-OMe 80 (0.29 g, 0.5 mmol) was taken up in dioxane (1 mL) 
and treated with N aI0 4  (0.13 g, 0.6 mmol) in water (1 mL). After stirring at room 
temperature for 5 h, the mixture was filtered then partitioned between EtOAc and 2% 
KHSO4  (10 mL each). The organic phase was washed successively with water (20 mL),
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5% NaHS0 3  (20 mL) and saturated NaCl solution (20 mL), dried over Na2S0 4  and 
evaporated to give crude 70 (230 mg). The crude product was purified by flash column 
chromatography (silica gel, MeOH-CHCb 1:9). Reverse phase analytical HPLC: linear 
gradient over 45 min of 100% solution A (0.1% TFA in H20 )  and 0% solution B (0.1% 
TFA in CH3CN-H2O 4:1), flow rate I mL/min over 40 min on a C4 column; tR = 34.1 
min. Amino acid analysis: 74.9%. Yield: 120 mg (41.4%). ‘H NMR (250 MHz, 
CD3OD) 8  0.81-0.96 (2d, 6 H, 2CH3), 2.15 (m, IH, CH(CH3)2), 3.12 (m, 4H, 2CH2Ph), 
3.59 (m, 4H, OCHCO+CH3 ), 4.05 (m, IH, CHCO), 4.48 (m, IH, CHPO), 4.99 (m, 2H, 
CH2(Z)), 7.22 (m, 15H, 3Ph); 31P (101 MHz, CD3OD) 8  18.8, 18.9; FAB-MS m/e 495.7 
(M+H)+.
Z-Phe-VaPF[(PO2 )O]-Phe-OAIIyl(50):
Compound Z-Phe-Val'P[(PHO)0]-Phe-0Allyl 81 (0.61 g, 1 mmol) was taken up in 
dioxane (2 mL) and treated with NaI0 4  (0.26 g, 1.2 mmol) in water (2 mL). After 
stirring at room temperature for 5 h, the mixture was filtered then partitioned between 
EtOAc and 2% K H S04 (20 mL each). The organic phase was washed successively with 
water (20 mL), 5% NaHS0 3  (20 mL) and saturated NaCl solution (20 mL), dried over 
Na2 S0 4  and evaporated the solvent to give crude product (612 mg). The crude product 
was purified by flash column chromatography (silica gel, MeOH-CHCb 1:12). Yield: 
269 mg (41%). Analytical HPLC: linear gradient over 55 min of 65% solution A (0.25M 
ammonium acetate in H20 )  and 35% solution B (0.05M ammonium acetate in CH3CN- 
H20  4:1), flow rate 1 mL/min on a SUPELCOSIL LC 18S column; tR= 15.07, 15.86 min. 
lH NMR (250 MHz, CD 3OD) 8  0.83-0.97 (2d, 6 H, 2CH3), 2.13 (m, IH, CH(CH3)2), 2.28 
(m, IH, CHCO) 3.10 (m, 4H, 2CH2Ph), 4.04 (m, IH, CHPO), 4.48 (m, 3H, CH=CH2+
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OCHCO), 5.18 (m, 2H, CH2(Z)), 5.32 (m, 2H, CH 2CH=CH2), 5.79 (m, IH, CH=CH2)
7.25 (m, 15H, 3Ph); 3lP (101 MHz, CD3 OD) 5 17.5; FAB-MS (NBA): m/e 622.5 
(M+H)+.
Z-Ala-AIa'F[(P02 )0]-Phe-0M e (77):
According to procedure of 70, staring with Z-Ala-AlaxP[(PHO)]-Phe-OMe 76 (91 mg, 0.2 
mmol) to yield Z-Ala-AlalP[(P0 2  )0]-Phe-0M e 77 (74 mg, 79%). 'H  NMR (250 MHz, 
CDCI3 ) 8  1.07-1.14(m, 6 H, 2CH3), 2.96 (m, IH, CHCO), 3.12 (m, 2H, CH 2 Ph), 3.70 (s, 
3H, OCH3), 3.78 (d, IH, OCHCO), 4.46 (m, IH, CHPO), 5.10 (m, 2H, CH 2(Z)), 5.27 (m, 
IH, NH), 7.28 (m, 10H, 2Ph); 31P (101 MHz, CDC13) 8  25.1 25.2, 26.2, 26.4; FAB-MS 
(NBA)/n/<? 491.1 (M-H)‘.
Z-Ala-Ala'P[(P02‘)0]-Phe-0Allyl (76):
According to procedure of 70, staring with Z-Ala-AlavF[(PHO)]-Phe-OAllyl 77 (214 mg, 
0.42 mmol) to yield Z-Ala-Ala4/[(P0 2 ')0]-Phe-0A llyl 76 (140 mg, 63%). Analytical 
HPLC: linear gradient over 65 min of 65% solution A (0.25M ammonium acetate in 
H2 0 ) and 35% solution B (0.05M ammonium acetate in CH3 CN-H20  4:1), flow rate 1 
mL/min on a SUPELCOSIL LC 18S column; tR= 17.23min. *H NMR (250 MHz, CDC13) 
8  1.07-1.38(m, 6 H, 2CH3), 2.93-3.31 (m, 3H, CHCO+CH 2 Ph), 4.46 (2d, IH, CHPO), 
4.65 (m, 2H, CH 2 CH=CH2), 5.09-5.31 (m, 3H, CH=CH 2 +CH2(Z)), 5.90 (m, IH, 
CH=CH2), 7.28 (m, 10H, 2Ph); 3,P (101 MHz, CDC13) 8  24.9; FAB-MS (NBA)m/e (M- 
H)' FAB-MS (NBA)m/e 516.6 (M-H)\
Z-Phe-Ala'P[(P02 )0]-Phe-0M e (73):
According to procedure o f 70, staring with Z-Phe-Ala'P[(PHO)]-Phe-OMe 82 (141 mg, 
0.26 mmol) to yield Z-Phe-AlaxP[(P0 2  )0]-Phe-0M e 73 (122 mg, 84%). lH NMR (250
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MHz, CDCI3 ) 8  1.07-1.33 (m, 3H, CH3), 3.03 (m, 2H, CH 2 Ph), 3.24 (t, IH, 
(OCH(Bz)CO), 3,78 (s, 3H, CH3), 4.22 (m, IH, CHCO), 4.46 (m, IH, CHPO), 5.08 (s, 
2H, CH 2(Z)), 7.23 (m, 10H, 2Ph); 3lP (101 MHz, CDC13) 5 24.2, 24.6,24.8; FAB-MS m/e
567.5 (M -H)\
Z -Phe-A la 'F [(P0 2 ')0]-Phe-O Allyl (72):
According to procedure o f 70, staring with Z-Phe-Ala4/[(PHO)]-Phe-OAUy 83 (116 mg, 
0.2 mmol) to yield Z-Phe-AlaxP[(P 0 2 )0]-Phe-0Allyl 72 (90 mg, 75 %). Analytical 
HPLC: linear gradient over 60 min of 95% solution A (0.1M TEAA in H20 )  and 5% 
solution B (0.02M TEAA in CH3 CN-H20  4:1), flow rate 1 mL/min on a C-18 column; tR 
=  23.5, 24.6 min.lH NMR (300 MHz, CDC13) 8  1.28 (m, 3H, CH3), 3.04 (m, 4H, 
2CH 2 Ph), 3.70 (m, IH, CHCO), 4.45 (m, IH, CHPO), 4.77 (m, 3H, OCHCO+CH=CH2), 
5.31 (m, 4H, CH 2(Z)+CH 2 CH=CH2), 5.89 (t, IH, CH=CH2), 7.26 (m, 15H, 3Ph); 3lP 
(121 MHz, CD 3 OD) 8  22.4, 23.1,24.0; FAB-MS (NBA): m/e 595.5 (M-H)‘. 
Z -Phe-V alT [(P0S*)0]-Phe-0M e (71):
Z-Phe-ValvF[(PHO)0]-Phe-OMe 80 (0.23 g, 0.4 mmol) was taken up in dioxane (1 mL) 
and treated with 5% sulfur in carbondisulfide-pyridine-TEA (9:9:1, 0.38 mL). After 
stirring at room temperature for 5 h, the mixture was filtered then partitioned between 
EtOAc and 2% KHSO4  (10 mL each). The organic phase was washed successively with 
water (15 mL), 5% NaHS0 3  (15 mL) and saturated NaCl solution (15 mL), dried over 
Na2 S0 4  and evaporated the solvent to give crude 71 (237 mg). The crude product was 
purified by flash column chromatography (silica gel, MeOH-CHCb 1:9). Amino acid 
analysis: 77%. Reverse phase analytical HPLC: linear gradient over 45 min of 100% 
solution A (0.1% TFA in H 2 0 )  and 0% solution B (0.1% TFA in CH3CN-H2 0  4:1), flow
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rate 1 mL/min over 40 min on a C4 column; tR = 34.1 min. Yield: 84 mg (37%). lH 
NMR (250 MHz, CDC13) 5 0.86-1.04 (m, 6 H, 2CH3), 2.45 (m, IH, CH(CH3)2), 2.82 (m 
IH, CHCO), 3.21 (m, 4H, 2CH 2 Ph), 3.59 (m, 3H, CH3), 4.10 (2d, IH, CHPO), 4.43 (m, 
IH, OCHCO), 4.89 (s, 2H, CH2(Z)), 7.23 (m, 15H, 3Ph); 3lP (101 MHz, CD3 OD) 8  76.4, 
76.8; FAB-MS m/e 611.7 (M+H)+.
Z-Phe-V am (PO S-)0]-Phe-O AIIyl(51):
Z-Phe-VallP[(PHO)0]-Phe-0Allyl 81 (0.47 g, 0.77 mmol) was taken up in dioxane (1.5 
mL) and treated with 5% Sulfur in Carbondisulfide-pyridine-TEA (9:9:1, 0.6 mL). After 
stirring at room temperature for 5 h, the mixture was filtered then partitioned between 
EtOAc and 2% KHSO4  (20 mL each). The organic phase was washed successively with 
water (30 mL), 5% NaHS0 3  (30 mL) and saturated NaCl solution (30 mL), dried over 
Na2S0 4  and evaporated to give crude Z-Phe-Val4/[(P0S')0]-Phe-0Allyl (510 mg). The 
crude product was purified by flash column chromatography (silica gel, MeOH-CHCl3 
1:12). Yield: 202 mg (41%). Analytical HPLC: linear gradient over 60 min of 65% 
solution A (0.25M ammonium acetate in H2 0 )  and 35% solution B (0.05M TEAA in 
CH3CN-H20  4:1), flow rate 1 mL/min on a SUPELCOSIL LC 18S column; tR= 28.8min. 
'H NMR (250 MHz, CD3OD) 8  0.74-1.04 (m, 6 H, 2CH3), 2.28 (m, IH, CH(CH3)2), 2.45 
(m, IH, CHCO) 3.13 (m, 4H, 2CH 2 Ph), 4.08 (m, IH, CHPO), 4.51 (m, 3H, CH=CH2+ 
OCHCO), 4.97 (m, 2H, CH2(Z)), 5.22 (m, 2H, CH 2CH=CH2), 5.88 (m, IH, CH=CH2)
7.25 (m, 15H, 3Ph); 31P (101 MHz, CDC13) 8  76.2, 76.5, 76.8; FAB-MS (GLY) m/e
638.6 (M+H)+.
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Z-Ala-AlavP[(P0S')0]-Phe-0Me (79):
According to procedure of 71, staring with Z-Ala-AlalF[(PHO)]-Phe-OMe 84 (97 mg, 0.2 
mmol) to yield Z-A la-Ala'F[(P0S)0]-Phe-0M e (95 mg, 94%). lH NMR (250 MHz, 
CDC13) 5 1.14-1.43(m, 6 H, 2CH3), 2.95 (m, IH, CHCO), 3.12 (m, 2H, CH2 Ph), 3.66 (d, 
IH, OCHCO), 3.74 (s, 3H, OCH3), 4.46 (m, IH , CHPO), 5.09 (m, 2H, CH2(Z)), 7.28 (m, 
10H, 2Ph); 3IP (101 MHz, CDCI3) 8  90.2, 90.4, 90.8, 91.2, 92.2; FAB-MS (NBA)m/e
506.9 (M-H)\
Z-Ala-Ala'P[(POS')0]-Phe-OAllyl (78):
According to procedure of 71, staring with Z-Ala-AlaxF[(PHO)]-Phe-OAllyl 85 (300 mg, 
0.6 mmol) to yield Z-Ala-Ala4,[(P0S')0]-Phe-0AUyl 78 (262 mg, 82%). Analytical 
HPLC: linear gradient over 60 min of 65% solution A (0.25M ammonium acetate in 
H20 )  and 35% solution B (0.05M ammonium acetate in CH 3CN-H2 0  4:1), flow rate 1 
mL/min on a SUPELCOSIL LC 18S column; tR = 15.82min. ‘H NMR (250 MHz, 
CDCI3 ) 8  1.07-1.45(m, 6 H, 2CH3), 2.36-3.19 (m, 3H, CHCO+CH 2 Ph), 4.45 (2d, IH, 
CHPO), 4.63 (m, 2H, CH 2CH=CH2), 5.04-5.37 (m, 3H, CH=CH2+CH2(Z)), 5.85 (m, IH, 
CH=CH2), 7.28 (m, 10H, 2Ph); 31P (101 MHz, CDC13) 8  76.3, 76.8, 77.0; FAB-MS 
(NBA)m/fe 533.3 (M-H)\
Z-Phe-Ala'F[(POS)0]-Phe-OMe (75):
According to procedure of 71, staring with Z-Phe-AlavP[(PHO)]-Phe-OMe 82 (150 mg, 
0.27 mmol) to yield Z-Phe-AlalP[(POS‘)0]-Phe-OMe 75 (119 mg, 76%). ‘H NMR (250 
MHz, CDCI3) 8  1.05-1.31 (m, 3H, CH3), 3.05 (m, 4H, CH 2Ph), 3.26 (t, IH, 
(OCH(Bz)CO), 3,77 (s, 3H, CH3), 4.25 (m, IH, CHCO), 4.47 (m, IH, CHPO), 5.08 (s,
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2H, CH 2 (z)), 7.23 (m, 10H, 2Ph); 3IP (101 MHz, CDC13) 8  74.8,75.3,76.1; FAB-MS m/e
585.4 (M-H)\
Z-Phe-Ala'F[(P0S')0]-Phe-0Allyl(74):
According to procedure of 71, staring with Z-Phe-Ala4/ [(PHO)]-Phe-OAlly 83 (116 mg, 
0.2 mmol) to yield Z-Phe-A la^O W O l-Phe-O A llyl 74 ( 8 6  mg, 70 %). Analytical 
HPLC: linear gradient over 60 min of 65% solution A (0.25M ammonium acetate in 
H20 )  and 35% solution B (0.05M ammonium acetate in CH3CN-H2 0  4:1), flow rate 1 
mL/min on a SUPELCOSEL LC 18S column; tR = 15.91 min. 'H  NMR (300 MHz, 
CDCI3 ) 5 1.24 (m, 3H, CH3), 3.08 (m, 4H, 2CH2 Ph), 3.68 (m, IH, CHCO), 4.47 (m, IH, 
CHPO), 4.75 (m, 3H, OCHCO+CH=CH2), 5.35 (m, 4H, CH 2®+CH 2 CH=CH2), 5.88 (t, 
IH, CH=CH2), 7.28 (m, 15H, 3Ph); 3,P (121 MHz, CD 3 OD) 8  76.7, 77.5, 78.3, 78.5; 
FAB-MS (NBA): m/e 609.4 (M-H)\
Methyl ester cleavage reagent:71
The cleavage reagent lithium n-mecaptide in heamethylphosphoramide (HMPA) was 
prepared by adding freshly n-propyl mercaptan (1 mL) to a suspension of ground lithium 
hydride (0.3 g) in pre-purged HMPA (10 mL) under argon, stirred for I h followed by 
nitration without contact with air. The reagent is stored at 0 °C without removal of the 
excess mercaptan. The concentration of mercaptide was 0.5-0.6 M.
General procedure for methyl ester cleavage:
The tripeptide phosphonate ester (0.22 mmol) was treated with 0.46 mmol lithium n- 
propyl mercaptide in 1 mL of hexamethyiphosphoramide (HMPA) and stirred at room 
temperature for 25 °C for 2.5 h. The reaction mixture was diluted with water and washed
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six times with CHCI3  to remove HMPA, and the aqueous phase was lyophilized to yield 
white powder. The crude product was purified by Sep-Pak purification:
The tripeptide analog sample (16 mg) was dissolved in 50 mM triethylammonium acetate 
(TEAA) (1 mL, could be less). Two-connected Qg Sep-Pak cartridges were washed with 
Water, MeOH, and 50 mM TEAA (5 mL each), then loaded with sample solution. Eluted 
sample with 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, and 80% CH3CN in 50 mM 
TEAA solution (5 mL each, 1 mL/fraction, 10 mL/min). Lyophilized all fractions, 
collected fractions with the same 3IP NMR signals.
Tetrakis(triphenylphosphine) palladium (0) :78
The catalyst tetrakis(triphenylphosphine) palladium (0) was prepared according to 
literature procedure. 7 3  The mixture of palladium dichloride (200 mg, 1.1 mmol) and 
triphenylphosphine (1.48 g, 5.6 mmol) in dimethyl sulfoxide (DMSO, 13.6 mL) was 
heated to 140 °C. Hydrazine hydrate (0.22 mL, 4.5 mmol) was then rapidly added. The 
dark solution was then immediately cooled with a water bath; crystallization begun to 
occur at 125 °C. After the mixture has reached the room temperature it was filtered under 
nitrogen on a funnel. The solid was washed with two 5 mL portions o f EtOH and two 5 
mL portions of diethyl ether. The product was dried by passing a slow steam o f nitrogen 
through the funnel overnight. The resulting yellow crystalline product was obtained 
(1.19g, 91% yield).
General procedure for allyl ester cleavage:
The tripeptide phosphonate ester (0.14 mmol) was dissolved in dichloromethane (4 mL). 
The solution was treated with morpholine (0.28 mmol) and Pd(P(Ph) 3 ) 4  (0.014 mmol). 
The mixture was stirred for 1 h, then added resin-bound PPh3 (0.28 mmol) for 1 h to
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remove Pd. The solid was filtered off, and the solution was dried. The crude product 
was purified by Sep-Pak purification.
General method for amino acid analysis
In a centrifugal tube was charged peptide sample (2 mg), isoleucine (10 nmol as 
reference standard), HC1 (37%, 1 mL) and propionic acid (1 mL). The solution was 
heated to 160 °C for 1 h to hydrolyze, cooled to room temperature to lyophilize. The 
residue was dissolved in HPLC grade water (250 mL). Then the solution (1 mL) was 
lyophilized. The residue was dissolved in 200 pL water. 50 pL solution was injected 
into amino acid analysis apparatus.
Z-Phe-VaPF[(P02')0]-Phe-OH (la):
Following the methyl ester cleavage procedure. Starting with Z-Phe-Val'P[(P02 ')0]Phe- 
Oallyl (49 mg, 0.08 mmol). Lyophilization yielded 32 mg of a white powder. The crude 
sample(16 mg) was loaded to Sep-Pak column and 13 mg oil-like triethylammonium salt 
was obtained. Amino acid analysis: 37%; yield: 21%. Analytical HPLC: linear gradient 
over 60 min o f 65% solution A (0.25M ammonium acetate in H20 )  and 35% solution B 
(0.05M ammonium acetate in CH 3 CN-H20  4:1), flow rate 1 mL/min over 60 min on a 
SUPELCOSIL LC 18S column; tR = 9.98, 10,49min. *H NMR (250 MHz, CD3OD) 8  
0.79-0.96 (m, 6 H, 2CH3), 2.19 (m, IH, CH(CH3)2), 3.14 (m, 4H, 2CH 2 Ph), 4.04 (m, IH, 
CHCO), 4.54 (m, IH, CHPO), 4.95 (m, 2H, CH 2(Z)), 7.21 (m, 15H, 3Ph); 3IP (101 MHz, 
CD3OD) 5 18.1, 18.4; FAB-MS m/e 580.8 ((M-H)'); HRMS (FAB (MNBA)) m/e calc’d 
for C3 0H 3 5 O8 N2P ((M-H)'): 581.2053; found 581.2038.
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Z-Phe-VaI'F[(P0S )0]-Phe-0H  (lb):
Following the methyl ester cleavage procedure. Starting with Z-Phe-ValvF[(POS )0]Phe- 
OMe (61 mg, 0.1 mmol). Lyophilization yielded 48 mg of a white powder. The crude 
sample (16 mg) was loaded to Sep-Pak column and 15 mg oil-like triethylammonium salt 
was obtained. Amino acid analysis: 49%; yield: 38%. Analytical HPLC: linear gradient 
over 60 min of 65% solution A (0.25M ammonium acetate in H20 )  and 35% solution B 
(0.05M ammonium acetate in CH3 CN-H20  4:1), flow rate 1 mL/min on a SUPELCOSIL 
LC 18S column; tR= 9.75, 10.52min. lH NMR (250 MHz, CD3OD) 6  0.90-1.02 (m, 6 H, 
2CH3), 2.20 (m, IH, CH(CH3)2), 3.22 (m, 4H, 2CH2 Ph), 4.15 (m, IH, CHCO), 4.56 (m, 
IH, CHPO), 5.01 (m, 2H, CH2(Z)), 7.20 (m, 15H, 3Ph); 3lP (101 MHz, CD3OD) 5 76.6; 
FAB-MS m/e 596.7 ((M-H) ); HRMS (FAB (MNBA)) m/e calc’d for C 3 0H3 5ON2PS (M-
H)*: 597.1824; found 597.1804.
Z-Phe-Ala'F[(P02)0]-Phe-OH (lc):
Following the allyl ester cleavage procedure. Starting with Z-Phe-Ala4/[(P0 2‘)0]Phe- 
OAllyl (90 mg, 0.12 mmol). Lyophilization yielded 80 mg of a white powder. The crude 
sample (40 mg) was loaded to Sep-Pak column and 40 mg oil-like triethylammonium salt 
was obtained. Analytical HPLC: linear gradient over 60 min of 95% solution A (0.1M 
TEAA in H 20 )  and 5% solution B (0.02M TEAA in CH3 CN-H20  4:1), flow rate 1 
mL/min on a C-18 column; tR= 28.75, 29.33 min. *HNMR (250 MHz, CD3OD) 5 0.86- 
0.97 (m, 3H, CH3), 2.07 (m, IH, CHCH3), 3.01 (m, 4H, 2CH2 Ph), 4.14 (m, IH, CHCO), 
4.52 (m, IH, CHPO), 5.03 (m, 2H, CH2(Z)), 7.19 (m, 15H, 3Ph); 31P (101 MHz, 
CD 3OD) 8  19.0, 19.3, 22.2, 22.4; FAB-MS m/e 553.3 ((M-H) ); HRMS (FAB (MNBA)) 
m/e calc’d fo rC 2 8H3 l0 8N2P (M-H)' 553.1739; found 553.1757.
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Z -A la-A laW 02)O]-Phe-0H (le):
Following the allyl ester cleavage procedure. Starting with Z-Ala-AlalP[(P0 2 ')0 ]Phe- 
Oallyl (32 mg, 0.062 mmol). Lyophilization yielded 27 mg of a white powder. The 
crude sample was loaded to Sep-Pak column and 19 mg oil-like triethylammonium salt 
was obtained. Analytical HPLC: linear gradient over 60 min of 95% solution A (0.1M 
TEAA in H 2O) and 5% solution B (0.05M TEAA in CH3 CN-H2O 4:1), flow rate 1 
mL/min over 60 min on a C-18 column; tR = 30.0 min. *H NMR (250 MHz, CD3OD) 8  
1.41-1.43 (m, 6 H, 2CH3), 2.01 (m, IH, CHCH3), 3.27 (dd, 4H, 2CH2 Ph), 3.65 (m, IH, 
CHCO), 4.36 (m, IH, CHPO), 5.06 (m, 2H, CH 2(z)), 7.25 (m, 10H, 2Ph); 3,P (101 MHz, 
CD3 OD) 8  19.0, 19.1, 19.2; FAB-MS m/e 476.9 (M-H)‘; HRMS (FAB (MNBA)) m/e 
calc’d for C2 2H27O8 N 2P ((M-H)'): 477.1426; found 477.1414. 
Z-Ala-Ala'P[(POS')0]-Phe-OH (If):
Following the allyl ester cleavage procedure. Starting with Z-Ala-Ala4/[(P0S')0]Phe- 
OAllyl (74 mg, 0.14 mmol). Lyophilization yielded 54 mg of a white powder. The crude 
sample (30 mg) was loaded to Sep-Pak column and 29 mg oil-like triethylammonium salt 
was obtained. Analytical HPLC: linear gradient over 60 min of 95% solution A (0.1M 
TEAA in H2 O) and 5% solution B (0.05M TEAA in CH3CN-H2O 4:1), flow rate 1 
mL/min over 60 min on a C-18 column; tR = 27.7 min. *H NMR (250 MHz, CD3 OD) 8  
1.31-1.36 (m, 6 H, 2CH3), 1.98 (m, IH, CHCH3), 3.16 (m, 4H, 2CH2 Ph), 3.60 (m, IH, 
CHCO), 4.14 (m, IH, CHPO), 5.08 (m, 2H, CH 2©), 7.26 (m, 10H, 2Ph); 3,P (101 MHz, 
CD3 OD) 8  76.5,76.8,77.7; FAB-MS m/e 493.8 (M-H)'.
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